<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Agent Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Infect Agent Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">439</journal-id><journal-id journal-id-type="pmc-domain">infagcan</journal-id><journal-title-group><journal-title>Infectious Agents and Cancer</journal-title></journal-title-group><issn pub-type="epub">1750-9378</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11892266</article-id><article-id pub-id-type="pmcid-ver">PMC11892266.1</article-id><article-id pub-id-type="pmcaid">11892266</article-id><article-id pub-id-type="pmcaiid">11892266</article-id><article-id pub-id-type="pmid">40059217</article-id><article-id pub-id-type="doi">10.1186/s13027-025-00643-5</article-id><article-id pub-id-type="publisher-id">643</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Amiri</surname><given-names initials="S">Sogand</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rasekh</surname><given-names initials="S">Shiva</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moezzi</surname><given-names initials="SMI">Seyed Mohammad Iman</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seifi</surname><given-names initials="N">Nadia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fatemi</surname><given-names initials="SA">Seyed Amirreza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fathi</surname><given-names initials="S">Shirin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bagheri</surname><given-names initials="A">Ashkan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4265-1499</contrib-id><name name-style="western"><surname>Negahdaripour</surname><given-names initials="M">Manica</given-names></name><address><email>negahdaripour@sums.ac.ir</email><email>manica.negahdaripour@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n3s4692</institution-id><institution-id institution-id-type="GRID">grid.412571.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 8819 4698</institution-id><institution>Student Research Committee, </institution><institution>Shiraz University of Medical Sciences, </institution></institution-wrap>Shiraz, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n3s4692</institution-id><institution-id institution-id-type="GRID">grid.412571.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 8819 4698</institution-id><institution>Pharmaceutical Sciences Research Center, </institution><institution>Shiraz University of Medical Sciences, </institution></institution-wrap>Shiraz, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Department of Pharmaceutics, School of Pharmacy, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n3s4692</institution-id><institution-id institution-id-type="GRID">grid.412571.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 8819 4698</institution-id><institution>Department of Pharmaceutical Biotechnology, School of Pharmacy, </institution><institution>Shiraz University of Medical Sciences, </institution></institution-wrap>P.O. Box 71345-1583, Shiraz, Iran </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">479098</issue-id><elocation-id>16</elocation-id><history><date date-type="received"><day>14</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-11 10:25:16.343"><day>11</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13027_2025_Article_643.pdf"/><abstract id="Abs1"><p id="Par1">Several high-risk types of human papillomaviruses (HPVs) are associated with cervical cancer and other malignancies. Despite the tremendous success of marketed prophylactic HPV vaccines for the past 18 years, cervical cancer remains a significant global challenge. A nearly 10% increase in new cervical cancer cases worldwide from 2020 to 2022 underscores the urgent need for enhanced vaccination efforts. Current HPV vaccines, including Cervarix&#174;, Gardasil&#174;, Gardasil&#174;9, Cecolin&#174;, and Walrinvax&#174; utilize VLP (virus-like particle) structures and have demonstrated significant efficacy. However, challenges such as type-limited coverage, cold-chain requirements, and affordability emphasize the critical need for further research and development of novel HPV vaccines. Some investigational vaccines, for instance, those using VLPs to carry protective antigens with broader coverage across different viral types, show promise for the future of cervical cancer prevention. Realizing this hope and making further progress still depend on the dedication and innovation of the scientists and authorities involved. This review focuses on both approved and investigational preventive vaccines, including also those designed for simultaneous prevention and therapy. Clinical trials are briefly reviewed, and potential strategies to advance vaccination against HPV-induced cervical cancer are summarized. This review emphasizes approaches that require further investigation in the future.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HPV</kwd><kwd>Human papillomavirus</kwd><kwd>Cervical cancer</kwd><kwd>Cancer vaccines</kwd><kwd>Vaccine immunogenicity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Cervical cancer (CxCa) ranked as the fourth most common cancer among women worldwide, with 661,021 newly diagnosed cases reported in 2022 [<xref ref-type="bibr" rid="CR1">1</xref>]. It is a leading cause of cancer-related mortality in women, causing nearly 350,000 deaths globally in the same year [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, CxCa is a significant contributor to maternal orphanhood, accounting for approximately 20% of cases worldwide, which leads to substantial social and economic implications that must be addressed [<xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, the control and elimination of CxCa is a public health priority.</p><p id="Par3">Carcinogenic human papillomavirus (HPV) types are identified as the principal risk factor for CxCa in over 99% of cases. HPV Infections are more prevalent than any other sexually transmitted infection globally [<xref ref-type="bibr" rid="CR4">4</xref>]. Additionally, CxCa shows a significant correlation with HIV infection, with studies showing that HIV infection contributes to a nearly six-fold increase in the incidence of CxCa. The highest incidence and approximately 94% of deaths due to CxCa occur in low- to middle-income countries, particularly sub-Saharan Africa, Southeast Asia, and Central America [<xref ref-type="bibr" rid="CR5">5</xref>], where access to HPV vaccination and screening programs is inadequate. This situation highlights crucial disparities in socioeconomic factors that influence healthcare standards [<xref ref-type="bibr" rid="CR2">2</xref>], especially since no specific genetic predisposition for CxCa has been documented [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par4">The significant relationship between CxCa and persistent infection with HPV has fostered optimism regarding the potential impact of HPV vaccination on reducing the CxCa burden. Vaccination efforts can focus either on prevention or treatment. Currently, all marketed HPV vaccines are prophylactic, although research into therapeutic vaccines is ongoing.</p><p id="Par5">Prophylactic vaccines are designed to generate immune protection by producing neutralizing antibodies (nAbs), primarily of the IgG type, while therapeutic vaccination aims to induce cell-mediated immunity, specifically targeting CD8<sup>+</sup> T cells against HPV [<xref ref-type="bibr" rid="CR7">7</xref>]. Since the introduction of Gardasil&#174;, the first approved HPV vaccine in 2006, prophylactic HPV vaccines have effectively prevented HPV infections and significantly reduced the burden of CxCa in some countries [<xref ref-type="bibr" rid="CR8">8</xref>]. Current prophylactic HPV vaccines are based on virus-like particles (VLPs) [<xref ref-type="bibr" rid="CR9">9</xref>], which primarily prevent HPV invasion by stimulating humoral immunity and generating nAbs that target the main HPV capsid protein, L1 [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par6">Despite significant advances in vaccination and the development of novel HPV vaccines, recent statistics from Globocan indicate that the incidence and mortality of CxCa are still on the rise globally (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Even in low-income regions of the United States, a recent reversal of the declining trend of CxCa has been observed [<xref ref-type="bibr" rid="CR11">11</xref>]. Furthermore, the World Health Organization (WHO) predicts a 16.9% increase in CxCa incidence and a 21.1% rise in the mortality rate by 2030 worldwide. These statistics and projections underscore the urgent need for developing novel approaches and strategies to control HPV infection through vaccination [<xref ref-type="bibr" rid="CR2">2</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Worldwide incidence and mortality caused by cervical cancer in 2020 and 2022, according to Global Cancer Statistics. New cases rose by approximately 9.42% in two years. The number of deaths slightly increased (1.86%). Although the greater number of cases of all cancers might explain the higher number of cases, the percentages of cases associated with cervix uteri incidence and mortality (versus all cancers) also slightly increased from 2022 to 2020 (3.3% vs. 3.1% and 3.6% vs. 3.4%, respectively [<xref ref-type="bibr" rid="CR1">1</xref>] [<xref ref-type="bibr" rid="CR176">176</xref>])</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13027_2025_643_Fig1_HTML.jpg"/></fig></p><p id="Par7">This paper aims to address this issue by first reviewing the structure and pathogenesis of HPV. It then summarizes the available and investigational prophylactic HPV vaccines, highlighting their platforms, efficacy, and outcomes in preventing CxCa. Additionally, the review succinctly discusses the types of vaccines that could bolster global CxCa prevention efforts in the future.</p></sec><sec id="Sec2"><title>Human papillomavirus (HPV)</title><sec id="Sec3"><title>Structure</title><p id="Par8">HPVs are nonenveloped icosahedral viruses containing circular double-stranded DNA. Their genome encodes six early proteins (E1, E2, E4, E5, E6, and E7), which play regulatory roles in replication and carcinogenesis, as well as two late proteins (L1 and L2) that form the capsid [<xref ref-type="bibr" rid="CR12">12</xref>]. Specifically, E1 and E2 aid in replication, E4 facilitates virus release, and E5, E6, and E7 promote host cell proliferation [<xref ref-type="bibr" rid="CR13">13</xref>]. Major (72 L1 pentamers) and minor (12&#8211;72 L2) proteins self-assemble and create the capsid [<xref ref-type="bibr" rid="CR10">10</xref>]. The infection process begins with the attachment of the virions to basal cell heparan sulfate proteoglycans (HSPGs). Subsequently, during virus integration, L1 and L2 are deleted. Consequently, vaccines targeting these proteins will be ineffective if HPV-related diseases have already developed [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec4"><title>HPV diversity</title><p id="Par9">HPVs are categorized into five main phylogenetic genera (&#945;, &#946;, &#947;, &#956;, and &#957;) according to the nucleotide sequence of the open reading frame (ORF) encoding the L1 protein. HPVs from different genera present less than 60% similarity in the L1 gene. In a genus, HPVs are grouped into species with 60 to 70% similarity. The International Human Papillomavirus Reference Center has identified 52 species and 228 subtypes of HPV, although only a limited number of these viruses are associated with health issues. Certain types of HPV can result in conditions such as genital warts, while others may lead to cancers of the cervix, vulva, vagina, oropharynx, or anus [<xref ref-type="bibr" rid="CR15">15</xref>]. To date, more than 200 HPV genotypes have been identified and classified into three groups based on their carcinogenic potency: high-risk (HR-HPV), potentially high-risk (pHR-HPV), and low-risk (LR-HPV). Fourteen types (HPV-16/18/31/33/35/39/45/51/52/56/58/59/66/68) are recognized as HR-HPVs for CxCa with varying probabilities of risk occurrence. LR-HPVs (HPV-6/11/40/42/43/44) are considered noncarcinogenic but can cause anogenital warts, such as condyloma acuminatum [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Notably, HPV-16 and &#8722;18 are the most common carcinogenic HR-HPVs and are involved in approximately 50 and 20% of CXCas, respectively [<xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, five &#945;&#8210;papillomaviruses (53/66/70/73/82) are recognized as pHR-HPVs due to limited data regarding their carcinogenicity [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec5"><title>Viral life cycle and pathogenesis</title><p id="Par10">HPV is responsible for the majority of sexually transmitted infections worldwide. The natural clearance of HPV typically occurs within the first two years following infection. However, if the infection persists, a variety of diseases, including genital warts and cancer, may arise [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par11">HPVs are viruses that infect the epithelial basal cells of the cervix and various other organs. The viral entry process begins when the virus binds to heparan sulfate proteoglycans (HSPGs) on the basement membrane [<xref ref-type="bibr" rid="CR20">20</xref>]. Following this binding, conformational changes occur in the virus, exposing the N-terminus of its L2 protein [<xref ref-type="bibr" rid="CR17">17</xref>]. This exposure facilitates the virus entry into keratinocytes. If the viral infection is not cleared, the virus then travels to endosomal compartments. After uncoating, it releases its genome into the cell nucleus through an L2-dependent mechanism. The viral genome can persist in an episomal state in basal cells&#8212;besides the host DNA&#8212;potentially leading to benign or precancerous lesions [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par12">In some cases, HPV can integrate into host DNA, disrupting host gene expression and producing oncoproteins, particularly E6 and E7. These oncoproteins interfere with key cell cycle regulatory proteins, promoting uncontrolled cell growth and contributing to malignant transformation [<xref ref-type="bibr" rid="CR21">21</xref>]. Following integration, other early genes&#8212;namely E1, E2, E4, and E5&#8212;as well as the late genes&#8212;L1 and L2&#8212;are deleted [<xref ref-type="bibr" rid="CR14">14</xref>]. This process can lead to cervical intraepithelial neoplasia (CIN) and, ultimately, cervical carcinoma [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec></sec><sec id="Sec6"><title>Prophylactic vaccines for cervical cancer (CxCa)</title><p id="Par13">Prophylactic vaccines targeting the L1 and L2 proteins of HPV, can inhibit the infectious cycle by promoting the production of antibodies against these targeted proteins. Upon viral entry into the cells, the antibodies produced following vaccination can recognize and neutralize the virus, leading to its subsequent elimination from the body. While L2-based vaccines are still in the investigational stages, several approved L1-based vaccines are already available on the market.</p><sec id="Sec7"><title>L1-based vaccines</title><p id="Par14">L1 is the major capsid protein in HPV, with a molecular weight (MW) of 55 kDa, representing 80% of the viral capsid proteins [<xref ref-type="bibr" rid="CR22">22</xref>]. The initial strategy for preventing HPV-induced CxCa involved the development of prophylactic vaccines containing the L1 protein. Currently, three L1-based HPV vaccines are licensed by the US FDA: Cervarix&#174;, Gardasil&#174;, and Gardasil&#174;9, all of which have demonstrated excellent clinical efficacy [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, three new prophylactic vaccines&#8212;Cecolin&#174;, Walrinvax&#174;, and Cervavac&#174;&#8212; have recently been licensed in China and India. These three new biosimilar vaccines are expected to broaden access to HPV vaccination due to their considerably lower costs than the originators. The cost of each Cecolin&#174; dose is about 55% to 65% lower than that of Gardasil&#174; or Cervarix&#174; in the Gavi program. Gavi Vaccine Alliance is an international organization that supports vaccination in low-income and low to middle-income countries [<xref ref-type="bibr" rid="CR25">25</xref>]. WHO has already prequalified Cecolin&#174; and Walrinvax&#174; [<xref ref-type="bibr" rid="CR25">25</xref>]. An <italic toggle="yes">E. coli</italic>-produced 9-valent vaccine is also under development in China by the manufacturer of Cecolin&#174;. This vaccine has been reported to be non-inferior to Gardasil&#174;9 in a head-to-head comparative immunogenicity study involving women aged 18&#8211;26 years in China [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par15">All marketed L1-based vaccines (listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) are produced using recombinant DNA technology in various hosts, allowing the L1 proteins to self-assemble into empty shells or VLPs. These particles typically vary in size and exhibit spherical or ellipsoidal shapes. Due to the three-dimensional structure of their VLPs, these vaccines should be stored at a refrigeration temperature of 2&#8211;8&#160;&#176;C [<xref ref-type="bibr" rid="CR27">27</xref>].<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Approved HPV vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Vaccine name</th><th align="left" colspan="1" rowspan="1">Company</th><th align="left" colspan="1" rowspan="1">Type and amount of L1 VLP</th><th align="left" colspan="1" rowspan="1">Year approved/ approving authority</th><th align="left" colspan="1" rowspan="1">Adjuvant</th><th align="left" colspan="1" rowspan="1">Expression system</th><th align="left" colspan="1" rowspan="1">Vaccination schedule [<xref ref-type="bibr" rid="CR28">28</xref>]*</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Cervarix&#174;</td><td align="left" colspan="1" rowspan="1">GlaxoSmithKline (GSK)</td><td align="left" colspan="1" rowspan="1"><p>20 &#181;g HPV-16,</p><p>20 &#181;g HPV-18</p></td><td align="left" colspan="1" rowspan="1">2009/ US-FDA</td><td align="left" colspan="1" rowspan="1">AS 04: 500 &#181;g aluminum hydroxide and 50 &#181;g 3-O-desacyl-4&#8217; monophosphoryl lipid A (MPL)</td><td align="left" colspan="1" rowspan="1">Baculovirus (insect) cells</td><td align="left" colspan="1" rowspan="1"><p>9&#8211;14 years: 2 doses with a minimum of 5-month interval</p><p>15 years and above: 3 doses administered at 0, 1&#8211;2, 6 months</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Gardasil&#174;</td><td align="left" colspan="1" rowspan="1">Merck Sharp &amp; Dohme (MSD)</td><td align="left" colspan="1" rowspan="1"><p>20 &#181;g HPV-6,</p><p>40 &#181;g HPV-11,</p><p>40 &#181;g HPV-16,</p><p>20 &#181;g HPV-18</p></td><td align="left" colspan="1" rowspan="1">2006/ US-FDA</td><td align="left" colspan="1" rowspan="1">225 &#181;g amorphous aluminum hydroxy phosphate sulfate</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Saccharomyces cerevisiae</italic></td><td align="left" colspan="1" rowspan="1"><p>9&#8211;13 years: 2 doses with a minimum of 5-month interval</p><p>14 years and above: 3 doses administered at 0, 1&#8211;2, 6 months</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Gardasil&#174;9</td><td align="left" colspan="1" rowspan="1">Merck Sharp &amp; Dohme (MSD)</td><td align="left" colspan="1" rowspan="1"><p>30 &#181;g HPV-6,</p><p>40 &#181;g HPV-11,</p><p>60 &#181;g HPV-16,</p><p>40 &#181;g HPV-18,</p><p>20 &#181;g HPV-31,</p><p>20 &#181;g HPV-33,</p><p>20 &#181;g HPV-45,</p><p>20 &#181;g HPV-52,</p><p>20 &#181;g HPV-58</p></td><td align="left" colspan="1" rowspan="1">2014/ US-FDA</td><td align="left" colspan="1" rowspan="1">500 &#181;g amorphous aluminum hydroxy phosphate sulfate</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. cerevisiae</italic></td><td align="left" colspan="1" rowspan="1"><p>9&#8211;14 years: 2 doses with a minimum of 5-month interval</p><p>15 years and above: 3 doses administered at 0, 1&#8211;2, 4&#8211;6 months</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Cecolin&#174;</td><td align="left" colspan="1" rowspan="1">Xiamen Innovax Biotech</td><td align="left" colspan="1" rowspan="1"><p>40 &#181;g HPV-16,</p><p>20 &#181;g HPV-18</p></td><td align="left" colspan="1" rowspan="1">2019/ China-FDA</td><td align="left" colspan="1" rowspan="1">208 &#181;g aluminum hydroxide</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Escherichia coli</italic></td><td align="left" colspan="1" rowspan="1"><p>9&#8211;14 years: 2-dose schedule at months 0, 6</p><p>15 years and above 3-dose schedule at 0, 1&#8211;2, 5&#8211;8 months</p></td><td align="left" colspan="1" rowspan="1"><p>[<xref ref-type="bibr" rid="CR32">32</xref>]</p><p>[<xref ref-type="bibr" rid="CR33">33</xref>]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Walrinvax&#174;</td><td align="left" colspan="1" rowspan="1">Walvax Yuxi Zerun Biotechnology Co</td><td align="left" colspan="1" rowspan="1"><p>40 &#181;g HPV-16,</p><p>20 &#181;g HPV-18</p></td><td align="left" colspan="1" rowspan="1">2022/ China-FDA</td><td align="left" colspan="1" rowspan="1">225 &#181;g aluminum phosphate</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pichia pastoris</italic></td><td align="left" colspan="1" rowspan="1"><p>9&#8211;14 years: 2-dose schedule at 0, 6 months</p><p>From age 15: 3-dose schedule at 0, 2&#8211;3, 6&#8211;7 months</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Cervavac&#174;</td><td align="left" colspan="1" rowspan="1">Serum Institute of India</td><td align="left" colspan="1" rowspan="1"><p>20 &#181;g HPV-6,</p><p>40 &#181;g HPV-11,</p><p>40 &#181;g HPV-16,</p><p>20 &#181;g HPV-18</p></td><td align="left" colspan="1" rowspan="1">2022/ Indian FDA</td><td align="left" colspan="1" rowspan="1">1.25 &#181;g Al<sup>3+</sup></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Hansenula polymorpha</italic></td><td align="left" colspan="1" rowspan="1"><p>9&#8211;26 years (girls and boys)</p><p>9&#8211;14 years: 2 doses at months 0, 6</p><p>15&#8211;26 years: 3-dose schedule at 0, 2, 6 months</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Off-label single-dose vaccination is already recommended by WHO (as of December 2022). The single-dose schedule for Cecolin&#174; was announced by WHO in October 2024</p><p>The dosage of all vaccines is 0.5 ml/dose. They are all administered via intramuscular (IM) injection in the deltoid region. All these vaccines should be kept at a refrigeration temperature of 2&#8211;8 &#176;C</p></table-wrap-foot></table-wrap></p><sec id="Sec8"><title>Cervarix&#174;</title><p id="Par16">Cervarix&#174;, marketed by GlaxoSmithKline in 2010, is a bivalent vaccine that contains HPV-16/18 VLPs (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>]. These two genotypes are the most oncogenic types of HPV, accounting for approximately 70% of CxCas and nearly 90% of anal cancers [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. This recombinant vaccine is produced in baculovirus (insect) cells and includes an adjuvant system, known as AS04, which consists of aluminum hydroxide and 3-O-desacyl-4&#8217; monophosphoryl lipid A (MPL). MPL is a detoxified derivative of lipopolysaccharide (LPS) derived from the Gram-negative <italic toggle="yes">Salmonella minnesota</italic> R595 strain [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec9"><title>Gardasil&#174;</title><p id="Par17">Gardasil&#174;, also known as Silgard&#174;, is a quadrivalent vaccine marketed by Merck Sharp &amp; Dohme that contains VLPs of HPV-6/11/16/18 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>]. Compared with Cervarix&#174;, the additional genotypes in Gardasil&#174; are responsible for approximately 90% of genital warts [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Approved in 2006, Gardasil&#174; is produced using <italic toggle="yes">Saccharomyces cerevisiae</italic> as the recombinant expression system, and it contains an adjuvant composed of 225 &#181;g of amorphous aluminum hydroxyphosphate sulfate [<xref ref-type="bibr" rid="CR38">38</xref>]. Studies have shown that Gardasil&#174; significantly reduces HPV infection in the anus, vulva, penis, and even the oral cavity [<xref ref-type="bibr" rid="CR40">40</xref>].</p></sec><sec id="Sec10"><title>Gardasil&#174;9</title><p id="Par18">Gardasil&#174;9 is a VLP-based nonavalent vaccine developed by Merck Sharp &amp; Dohme, containing HPV-6/11/16/18/31/33/45/52/58. The additional genotypes included in Gardasil&#174;9 account for another 20% of CxCa cases, indicating the vaccine&#8217;s potential to prevent nearly 90% of CxCa occurrence [<xref ref-type="bibr" rid="CR41">41</xref>]. It was approved in 2014 for both females and males (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec11"><title>Cecolin&#174;</title><p id="Par19">Cecolin&#174;, developed by Xiamen Innovax Biotech in China, contains 40 &#181;g of HPV-16 and 20 &#181;g of HPV-18 recombinant L1 VLPs. <italic toggle="yes">Escherichia coli</italic> is the expression system used for its production. This vaccine contains an aluminum hydroxide vaccine adjuvant. Cecolin&#174; successfully completed a Phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01735006">NCT01735006</ext-link>), demonstrating high efficacy and tolerability [<xref ref-type="bibr" rid="CR32">32</xref>], and it was approved by China's National Medical Products Administration in 2019. In October 2021, this vaccine received prequalification from the WHO. In March 2023, Cecolin&#174; was licensed in multiple low- to middle-income countries such as Bangladesh, Morocco, Nepal, Thailand, the Democratic Republic of Congo, and Cambodia [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="Sec12"><title>Walrinvax&#174;</title><p id="Par20">Walrinvax<bold>&#174;</bold> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) is a bivalent VLP-based L1 vaccine, targeting HPV-16 and &#8722;18, produced in <italic toggle="yes">Pichia pastoris</italic>. Walrinvax&#174; consists of 40 &#181;g of HPV-16 and 20 &#181;g of HPV-18 L1 protein VLPs adsorbed to 225 &#181;g of aluminum phosphate and suspended in 0.5 ml of buffered saline (0.32 M sodium chloride, 10 mM L-histamine, 0.025 &#181;g polysorbate 80) [<xref ref-type="bibr" rid="CR43">43</xref>]. Walrinvax<bold>&#174;</bold> is designed for intramuscular (IM) administration in women of 9&#8211;30 years. Developed by Shanghai Zerun Biotech Co., China, clinical trials for this vaccine are conducted in this country [<xref ref-type="bibr" rid="CR34">34</xref>]. In August 2024, Walrinvax&#174; received prequalification from the WHO, making it the fifth HPV vaccine available.</p></sec><sec id="Sec13"><title>Cervavac&#174;</title><p id="Par21">Cervavac<bold>&#174;</bold> is a quadrivalent vaccine (HPV-6/11/16/18) developed by the Serum Institute of India (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). It is approved for both females and males aged 9&#8211;26 years in India [<xref ref-type="bibr" rid="CR35">35</xref>]. This VLP vaccine uses Al<sup>3+</sup> as an adjuvant and can increase the IgG geometric mean titer to more than 1000 times the baseline value [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec14"><title>Dosing and age of vaccination</title><p id="Par22">Generally, the best time for vaccination to achieve maximum protection is before HPV exposure, since these preventive vaccines may not be effective against an existing infection. Thus, vaccination is usually recommended before sexual exposure commences [<xref ref-type="bibr" rid="CR45">45</xref>]. The optimal starting age is 11&#8211;12 years. The approved vaccination age range for Gardasil&#174; and Cervarix&#174; is between 9 and 26 years and is 9&#8211;45 years for Gardasil&#174;. However, the vaccination schedule varies depending on the vaccine&#8217;s first administration [<xref ref-type="bibr" rid="CR28">28</xref>]. Usually, if the first dose is administered at age 15, a two-dose schedule is recommended, with a minimum of a 5-month interval between the two doses (the optimal time is 6&#8211;12 months after the first dose). If the second dose is given within the first 5 months, a third dose is needed 4 months after the second dose. A three-dose vaccination plan is recommended to ensure efficacy if the initial vaccination age is over 15&#160;years. If the schedule is interrupted, there is no need to restart, and vaccinations can continue as scheduled [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, the three-dose schedule is also recommended for individuals with a weakened immune system aged 9&#8211;26 years [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Notably, as of December 2022, WHO has recommended a one- or two-dose schedule for girls aged 9&#8211;14 and girls and women aged 15&#8211;20 years [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. WHO updated its recommendations for the HPV vaccination schedule in early October 2024 to introduce a single-dose schedule of Cecolin&#174; as an alternative that demonstrated efficacy and protection durability comparable to the previous two-dose schedule [<xref ref-type="bibr" rid="CR25">25</xref>], following the previously announced off-label alternative schedule for using one single dose of HPV vaccines. The single-dose regimen was proposed as an off-label schedule. Single-dose vaccination against HPV has been gaining popularity; its usage increased from 20% in 2022 to 27% in 2023, with adoption by 23 countries in 2023.</p><p id="Par23">All three US FDA-approved vaccines (Cervarix&#174;, Gardasil&#174;, and Gardasil&#174;9) are extremely safe and well-tolerated at all ages [<xref ref-type="bibr" rid="CR51">51</xref>]. The most common side effects of Cervarix&#174; and Gardasil&#174; are injection site reactions, including pain and swelling. However, Cervarix&#174; may cause several systemic adverse effects, including fever, dizziness, myalgia, vomiting, nausea, and diarrhea [<xref ref-type="bibr" rid="CR52">52</xref>]. Moreover, considering their manufacturing process, Gardasil&#174; and Gardasil&#174;9 are not recommended for people with hypersensitivity to yeasts because of the risk of anaphylactic reactions [<xref ref-type="bibr" rid="CR53">53</xref>]. Fortunately, no significant observations have been made regarding the relationship between HPV vaccination and the new onset of autoimmune diseases, and studies have shown no serious adverse effects in people with medical conditions or pregnant women. Nevertheless, due to the lack of enough evidence for vaccination during pregnancy, postponing vaccination after childbirth is recommended [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par24">The recommended dosing methods for Cecolin&#174;, Walrinvax&#174;, and Cervavac&#174; are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Notably, the minimum protective antibody titer is still unknown, although some evidence indicates that one immunization dose might be protective enough [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In 2023, a mathematical modeling study published by B&#233;nard and colleagues recommended the one-dose HPV vaccine strategy for children aged 9&#8211;14 years based on a calculated protection time of more than 20&#8211;30 years using the nonavalent vaccine. The single-dose regimen will be especially beneficial in low- and middle-income countries, as it expands access to HPV vaccines by reducing costs and facilitating administration [<xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="Sec15"><title>Advantages of current HPV vaccines</title><p id="Par25">The VLP structure of approved HPV vaccines offers multiple benefits, including the dense and repetitive display of antigens on the particle surface [<xref ref-type="bibr" rid="CR57">57</xref>], resembling the conformation of real virions. Additionally, VLPs are noninfectious and non-oncogenic because VLPs lack viral genomes. Thus, as a class of subunit vaccines, they are safer than attenuated vaccines [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Moreover, reports suggest that HPV L1 VLPs stimulate the production of several polyclonal antibodies, including nAbs, in the host. This humoral response is 10 to 100 times stronger than that generated by natural infection [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. A comparison of the long-term efficacy of different HPV vaccines in a systematic review reported the longest period of sustained clinical effect for the quadrivalent Gardasil&#174; vaccine, which has been 12 years in real-world data and 14 years of seropositivity in the FUTURE II trial. Notably, similar outcomes are expected from the nonavalent vaccine; however, owing to its more recent introduction, a longer evaluation report is not yet available [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. The high impact of vaccines on cancer prevention has been recorded in many countries. Notably, a recent publication from Scotland reported no cases of CxCa in women vaccinated at 12&#8211;13 years of age during 12 years of follow-up [<xref ref-type="bibr" rid="CR64">64</xref>]. Although longer follow-up studies are still needed to fully assess the long-term benefit of these vaccines, their effectiveness in reducing cancer incidence is widely recognized.</p></sec><sec id="Sec16"><title>Limitations of current HPV vaccines</title><p id="Par26">While the current L1-VLP prophylactic vaccines are sufficiently effective, efforts are underway to develop improved vaccines due to some barriers to the uptake of these vaccines at the global level. Some of these barriers are related to specific countries and particularly their socioeconomic conditions, which are beyond the scope of this review. The major shortcomings of these vaccines, which contribute to their limited uptake, along with suggested approaches to address these issues, are summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. One disadvantage of L1 VLP vaccines is their type-restricted immunity leading to incomplete prevention in regards of other HPV genotypes. Protection against several non-vaccine HPV genotypes&#8211;notably HPV-31, &#8722;45, and HPV-33/52/58&#8211;is reported to be stronger by Cervarix&#174; than Gardasil&#174;, probably due to its adjuvant system. Though L1-based vaccines might provide limited cross-protection for heterologous HPV viruses in general, some other oncogenic HPV genotypes are not covered by vaccination [<xref ref-type="bibr" rid="CR65">65</xref>]. Moreover, the waning of cross-protection is observed. Besides, there is a risk of the emergence of viral types not covered by the vaccines over time. A report from Spain documented a higher incidence of several HPV types not covered by Cervarix&#174; and Gardasil&#174; vaccines, including HPV-31, HPV-52, and HPV-45 [<xref ref-type="bibr" rid="CR66">66</xref>]. The emergence of virus types uncovered by marketed vaccines could be a serious concern, especially in the long term. The partial type-specific immunity provided by current L1 vaccines also necessitates more extensive manufacturing processes, because each VLP type included in the vaccine must be produced separately and combined later to create the final vaccine formulation. The VLP manufacturing process, which requires creating stable particles free from contamination and impurities, imposes challenges and increases costs [<xref ref-type="bibr" rid="CR67">67</xref>]. Thus, scientists have sought novel ways to achieve broader cross-protection [<xref ref-type="bibr" rid="CR45">45</xref>]. Furthermore, studies indicate regional variations in HPV genotypes and vaccine efficacy, necessitating post-vaccination cervical screening programs. However, these screening programs can be costly and not all women may adhere to them in a timely manner [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. The high cost of these vaccines has significantly hindered vaccination progress, particularly in low- to moderate-income populations and developing countries [<xref ref-type="bibr" rid="CR70">70</xref>]. In response to supply limitations and high costs of Gardasil&#174;, Gardasil&#174;9, and Cervarix&#174;, countries such as China and India have initiated research and development of vaccines such as Cecolin&#174;, Walrinwax&#174;, and Cervavac&#174; to support global CxCa elimination efforts. Moreover, L1 vaccines require constant refrigeration at the optimal temperature, and exposure to extreme temperatures during storage or transfer can reduce their efficacy. This also increases vaccination costs [<xref ref-type="bibr" rid="CR71">71</xref>] and restricts access to these vaccines in remote areas. Given the higher rates of HPV cancers in some developing countries&#8211;particularly in parts of Africa&#8211;and the limited infrastructure in rural areas, the ease of transport, storage, and administration is crucial for successful vaccination programs [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Limitations of the current VLP prophylactic HPV vaccines and some suggested approaches to solve these issues (the limitations discussed here are related mainly to vaccine characteristics, not their social acceptance and similar aspects)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Characteristic of current vaccines</th><th align="left" colspan="1" rowspan="1">Limitation</th><th align="left" colspan="1" rowspan="1">Approaches to solve the issue</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Type-specificity (partial)</td><td align="left" colspan="1" rowspan="1"><p>1. Lack of complete cross-protection against other HPV types that are not included in the vaccine</p><p>2. More complex and lengthy manufacturing processes due to the inclusion of multiple types of HPV, which should be produced separately</p><p>3. The increased cost of vaccines for adding more HPV genotypes</p><p>4. The need for cancer screening remains</p><p>5. Risk of emergence of some uncovered HPV types</p></td><td align="left" colspan="1" rowspan="1">Employing protective L2 proteins of HPV in the vaccine (either exclusively or in combination with L1) to enhance cross-protection due to the higher conservancy of L2</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">No therapeutic indication</td><td align="left" colspan="1" rowspan="1">Not indicated for patients who already have cervical cancer</td><td align="left" colspan="1" rowspan="1">Developing therapeutic vaccines targeting the E proteins of HPV</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">High costs of vaccine</td><td align="left" colspan="1" rowspan="1">Lower access to vaccines, especially for low-income populations</td><td align="left" colspan="1" rowspan="1"><p>1. Development of vaccines with lower costs, for example, using simpler hosts (such as <italic toggle="yes">E. coli</italic>) (already done: Cecolin&#174; and Walrinvax&#174;)</p><p>2. Encouraging local production of HPV vaccines in low- and middle-income countries</p></td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Cold-chain requirement</td><td align="left" colspan="1" rowspan="1"><p>1. Increasing manufacturing, storage, and transfer costs</p><p>2. Not easy handling</p></td><td align="left" colspan="1" rowspan="1"><p>1. Lyophilized powder formulations</p><p>2. Developing vaccines with more stability at room temperature, such as peptide vaccines</p></td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Injectable formulation</td><td align="left" colspan="1" rowspan="1"><p>Need for nurses or other professionals for injecting vaccines</p><p>Not preferred by individuals with a fear of injection</p></td><td align="left" colspan="1" rowspan="1">Development of non-parental formulations such as intranasal or oral vaccines</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Need for multiple dosing *</td><td align="left" colspan="1" rowspan="1">Lower compliance for getting the vaccine, especially in remote areas</td><td align="left" colspan="1" rowspan="1"><p>1. Optimizing vaccination schedules</p><p>2. Reminder or call services</p></td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Effective only in the early stages of the viral life cycle</td><td align="left" colspan="1" rowspan="1">Age limitation (The greatest benefit of the vaccine occurs when vaccination is completed before age 15, particularly prior to the onset of sexual activity. However, individuals vaccinated after age 15 still gain some benefit, though it is lower than those who began the HPV vaccine injection before turning 15.)</td><td align="left" colspan="1" rowspan="1">Development of novel vaccines targeting other proteins that are present in later stages of the disease, such as the&#160;E proteins of HPV</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Single-dose vaccination is already recommended by WHO (off-label)</p></table-wrap-foot></table-wrap></p><p id="Par27">The limitations of current HPV vaccines have spurred the development of second-generation vaccines, such as L2-based vaccines. These vaccines aim to overcome the issue of type-specificity and could potentially work against a wider range of HPV genotypes, offering hope for future advancements in HPV vaccine development.</p><p id="Par28">Given the prophylactic nature of current L1 vaccines and their lack of efficacy against existing infections, ir is crucial to develop a therapeutic vaccine or a combination of therapeutic and preventive vaccines. This approach could greatly enhance the effectiveness of HPV vaccines and is an active area of research and development [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Post-translational proteins E6 and E7 can be used as antigenic candidates for therapeutic vaccines, as high concentrations of these proteins are consistently found in CxCa cases [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Some studies have also included E5 in addition to E6 and E7 [<xref ref-type="bibr" rid="CR76">76</xref>&#8211;<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par29">Research on therapeutic vaccines is ongoing, as discussed elsewhere [<xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref>]. Chimeric L1&#8210;L2 VLPs have also been explored as alternative preventive vaccines [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>].</p></sec><sec id="Sec17"><title>Under development L1-based vaccines</title><p id="Par30">To reduce the manufacturing costs of VLP L1-based HPV vaccines, simpler expression systems, such as <italic toggle="yes">E. coli,</italic> have been employed. The manufacturer of Cecolin&#174; (Xiamen Innovax Biotech, China) is working on a nonavalent vaccine (HPV-6/11/16/18/31/33/45/52/58) produced in <italic toggle="yes">E. coli</italic>, which is currently in Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05056402">NCT05056402</ext-link>). Other examples include the Quadri (HPV-6/11/16/18) and nonavalent (HPV-6/11/16/18/31/33/45/52/58) L1 VLP vaccines, both developed by Shanghai Bovax Biotechnology using <italic toggle="yes">Hansenula polymorpha</italic> (a methylotrophic yeast), which are currently in Phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04425291">NCT04425291</ext-link>). Several other companies engaged in the development of L1 HPV vaccines, including a trivalent vaccine by the Health Guard, China (HPV-16/18/58), which is in the preclinical phase [<xref ref-type="bibr" rid="CR84">84</xref>]; a bivalent vaccine by Shanghai Zerun Biotechnology (HPV-16/18); a tetravalent vaccine by the China National Biotech Group (HPV-16/18/52/58); and another tetravalent vaccine by the Serum Institute of India (HPV-6/11/16/18) [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par31">The most recent and innovative prophylactic HPV vaccine is likely the eleven-valent vaccine, developed by the National Vaccine and Serum Institute in China, which is currently undergoing a Phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05262010">NCT05262010</ext-link>) [<xref ref-type="bibr" rid="CR87">87</xref>]. The mentioned vaccines are listed in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>L1-based vaccines in different Phase 2/3 clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Vaccine</th><th align="left" colspan="1" rowspan="1">Company</th><th align="left" colspan="1" rowspan="1">Type of included HPV VLP</th><th align="left" colspan="1" rowspan="1">Clinical phase</th><th align="left" colspan="1" rowspan="1">Expression system</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Bivalent vaccine</td><td align="left" colspan="1" rowspan="1">Xiamen Innovax Biotech</td><td align="left" colspan="1" rowspan="1">HPV-16/11</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Escherichia coli</italic></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Quadrivalent vaccine</td><td align="left" colspan="1" rowspan="1">Shanghai Bovax Biotechnology</td><td align="left" colspan="1" rowspan="1">HPV-6/11/16/18</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Hansenula polymorpha</italic></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Nonavalent vaccine</td><td align="left" colspan="1" rowspan="1">Shanghai Bovax Biotechnology</td><td align="left" colspan="1" rowspan="1">HPV-6/11/16/18/31/33/45/52/58</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">H. polymorpha</italic></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Nonavalent vaccine</td><td align="left" colspan="1" rowspan="1">Xiamen Innovax Biotech</td><td align="left" colspan="1" rowspan="1">HPV-6/11/16/18/31/33/45/52/58</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">11-valent vaccine</td><td align="left" colspan="1" rowspan="1">National Vaccine and Serum Institute, China</td><td align="left" colspan="1" rowspan="1">HPV-6/11/16/18/31/33/45/52/58/59/68</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">H. polymorpha</italic></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">EG-HPV</td><td align="left" colspan="1" rowspan="1">Eyegene Inc., Korea</td><td align="left" colspan="1" rowspan="1">HPV-16/18</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">Yeast</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par32">Furthermore, several alternative approaches have demonstrated significant efficacy in preclinical phases. For instance, bacterial vectors, specifically, live attenuated <italic toggle="yes">Shigella</italic>, have been employed to deliver HPV-16/58 L1 proteins [<xref ref-type="bibr" rid="CR92">92</xref>]. Additionally, L1 capsomers (particularly HPV-16) have shown promise. As subunits of capsids, capsomers are more cost-effective and can be more easily replicated in recombinant bacteria, such as <italic toggle="yes">E. coli</italic> [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Their thermostability may address the challenges associated with the preservation of VLPs [<xref ref-type="bibr" rid="CR95">95</xref>].</p></sec></sec><sec id="Sec18"><title>L2-based vaccines</title><p id="Par33">Many studies have been conducted to develop second-generation HPV vaccines using L2 capsid proteins. While L1-based vaccines have been proven to be highly effective, L2-based vaccines are being investigated mainly to enhance cross-protection against different types of HPVs because the L2 protein is highly conserved across various HPV types [<xref ref-type="bibr" rid="CR10">10</xref>]. Studies have shown that nAbs can recognize L2 as a broadly protective antigen [<xref ref-type="bibr" rid="CR96">96</xref>]. Certain L2 residues are conserved among multiple HPV types. Research on the L2 protein has shown that its first 120 amino acids (aa) at the N-terminus constitute the only region exposed to the external environment throughout the viral life cycle, making it a potential target for vaccine design [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. This region plays a crucial role in virion assembly and infection. Additionally, it contains several highly conserved protective epitopes, including aa 17&#8211;36 [<xref ref-type="bibr" rid="CR98">98</xref>], 69&#8211;81 [<xref ref-type="bibr" rid="CR99">99</xref>], and 108&#8211;120 [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>] of the HPV-16 L2 protein.</p><p id="Par34">Given the linearity of L2 epitopes, they can be produced cost-effectively in <italic toggle="yes">E. coli</italic>. Additionally, L2 epitope peptides can be integrated into various scaffolds. They can also be fused to toll-like receptors (TLRs) as adjuvants in the design of multi-epitope polypeptide vaccines [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Generally, peptide-based epitope vaccines offer several advantages, including enhanced stability (which allows for less temperature-strict conditions for storage and transport), improved safety, reduced risk of triggering harmful autoimmune responses, and ease of production [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par35">However, immune responses to L2 vaccines, whether administered alone or in conjunction with a potent adjuvant, are generally lower than those elicited by the currently approved L1-based VLP vaccines [<xref ref-type="bibr" rid="CR106">106</xref>]. This discrepancy is primarily attributed to the linearity of L2 vaccines, which results in a deficiency in T-helper cell activity [<xref ref-type="bibr" rid="CR107">107</xref>]. Several strategies can potentially enhance the immunogenicity of this category of vaccines, including the use of VLP platforms, multimeric L2 peptides, recombinant bacteria as carriers for L2, the fusion of immunostimulatory agents, and DNA/mRNA vaccine platforms. While some of these strategies have demonstrated acceptable levels of immunogenicity, the exceptionally high efficacy of the present L-1-based vaccines has set high expectations for future vaccine development [<xref ref-type="bibr" rid="CR57">57</xref>]. Multi-epitope polypeptide vaccines remain less immunogenic than L1-VLPs due to their lack of complex conformational structures. However, given their broader protective spectrum, their lower immunogenicity may be considered acceptable if they can generate adequate serum antibody titers compared to current vaccines [<xref ref-type="bibr" rid="CR102">102</xref>]. Consequently, research in this area is ongoing. Various approaches have been undertaken to develop effective L2-based vaccines, as discussed below. The L2-based HPV vaccines that are currently in the preclinical phases are listed in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>, and one vaccine that has progressed to clinical trial is presented in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Preclinical studies of L2-based HPV vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Vaccine platform</th><th align="left" colspan="1" rowspan="1">Used adjuvant</th><th align="left" colspan="1" rowspan="1">Employed antigens</th><th align="left" colspan="1" rowspan="1">Expression system</th><th align="left" colspan="1" rowspan="1">Type of study</th><th align="left" colspan="1" rowspan="1">Type of immune response</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">Alum-MPL</td><td align="left" colspan="1" rowspan="1">RG1 epitope (HPV-16 L2 aa 17&#8211;36</td><td align="left" colspan="1" rowspan="1">Insect cells</td><td align="left" colspan="1" rowspan="1">In vitro (rabbit)</td><td align="left" colspan="1" rowspan="1"><p>Passive transfer of sera-protected mice against PsVs of HPV-16/18/45/31/33/52/58/35/39/51/59/68/56/73/26/53/66/34 and LR-HPV-6/43/44</p><p>nAbs against HR-HPV- 16/18/45/37/33/52/58/35/39/51/59/68/73/26/69/34/70, LR-HPV-6/11/32/40, and cutaneous HPV-2/27/3/76 in PBNA</p></td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">Alum/MPL</td><td align="left" colspan="1" rowspan="1">RG1 epitope</td><td align="left" colspan="1" rowspan="1">Sf9 insect cells</td><td align="left" colspan="1" rowspan="1"><p>In mice (RG1-VLP&#8201;+&#8201;HPV-18 L1-VLP)</p><p>In rabbits</p></td><td align="left" colspan="1" rowspan="1"><p>Cross-protection against vaginal challenge with HR-HPV-58</p><p>Cross-neutralization titers (50&#8211;1000) against HR-HPV-18/31/33/45/52/58/26/70</p></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">Alum-MPL</td><td align="left" colspan="1" rowspan="1">HPV-31 L2 (aa.17&#8211;38)</td><td align="left" colspan="1" rowspan="1">Bac-to-Bac baculovirus</td><td align="left" colspan="1" rowspan="1">In vivo (mice)</td><td align="left" colspan="1" rowspan="1">Cross-nAbs against HPV-2/5/6/11/16/18/27/31/33/35/39/52/57/58/59/68</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">Freund adjuvant</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L2 aa108-120</p><p>aa 56&#8211;81</p><p>aa 17&#8211;36</p><p>BPV-1 L2 aa 1&#8211;88</p></td><td align="left" colspan="1" rowspan="1">Insect cells</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo (mice)</p></td><td align="left" colspan="1" rowspan="1"><p>Most vaccinated mice could neutralize HPV-16 PsVs</p><p>nAbs against HPV-16</p><p>nAbs against HPV-16</p><p>No nAbs</p></td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">Alum-MPL</td><td align="left" colspan="1" rowspan="1">HPV-58 L2 aa.16&#8211;37</td><td align="left" colspan="1" rowspan="1">Baculovirus</td><td align="left" colspan="1" rowspan="1">In vivo (rabbits and mice)</td><td align="left" colspan="1" rowspan="1">nAbs against HPV-2/5/6/11/16/18/27/31/33/35/39/45/52/57/58/59/68</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1"><p>Alum with BECC470</p><p>(Bacterial enzymatic combinatorial chemistry)</p></td><td align="left" colspan="1" rowspan="1">HPV-16-L2 17&#8211;36 a.a. (RG1 epitope)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Yersinia pestis</italic></td><td align="left" colspan="1" rowspan="1">In vitro and in vivo</td><td align="left" colspan="1" rowspan="1">nAbs against HPV-16/18/39</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">HPV-16 L2</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pichia pastoris</italic></td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">Positive reaction against L1-HPV-16 antibody and L2 -HPV-16 antibody</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">HPV-18 L1 VLP</td><td align="left" colspan="1" rowspan="1">AS04</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L1, HPV-18 L1, and recombinant L2 fragment consisting of HPV-33 and HPV-58</p><p>(HPV-33 L2 (aa 17&#8211;36)&#8201;+&#8201;HPV-58 L2 (aa 56&#8211;75))</p></td><td align="left" colspan="1" rowspan="1">pAcSG2 baculovirus</td><td align="left" colspan="1" rowspan="1">In vivo (mouse and rabbit)</td><td align="left" colspan="1" rowspan="1">Protection against HPV-6/11/16/31/35/39/45/58/59 PsVs or quasivirions</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR115">115</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">HPV-18 L1 VLP</td><td align="left" colspan="1" rowspan="1">Alum-MPL</td><td align="left" colspan="1" rowspan="1"><p>HPV-45 L2</p><p>(aa 16&#8211;35)</p></td><td align="left" colspan="1" rowspan="1">Sf9 insect cells</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo (rabbits)</p></td><td align="left" colspan="1" rowspan="1"><p>nAbs against HPV-18/39/45/68/70</p><p>Passive transfer of sera-protected vaginal challenge of mice with PsVs of HPV-18/39/45/68</p></td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR116">116</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L1</p><p>HPV-5 L1</p><p>HPV-1 L1</p><p>HPV-16/18 L1</p></td><td align="left" colspan="1" rowspan="1">Alum-MPL</td><td align="left" colspan="1" rowspan="1"><p>HPV-17 L2 RG1</p><p>HPV-17 L2 RG1</p><p>HPV-4 L2 RG1</p><p>HPV-5 L2 aa53-72</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Spodoptera frugiperda</italic> (Sf9) insect cell</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1"><p>PsVs neutralized in L2-based PBNA:</p><p>HPV-5/8/20/23/24/36/49/80</p><p>HPV-20/24/36/92</p><p>HPV-4</p><p>No nAb in L2-based PBNA</p></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">HPV-16 L1 VLP</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L2</p><p>aa 108&#8211;120</p><p>aa 65&#8211;81</p><p>aa 56&#8211;81</p><p>aa 17&#8211;36</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1"><p>PsVs neutralized in PBNA:</p><p>HPV-16/58</p><p>HPV-11/16/18</p><p>HPV-18</p><p>No nAb</p></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">MS2 bacteriophage VLP</td><td align="left" colspan="1" rowspan="1">Incomplete Freund&#8217;s adjuvant</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L2</p><p>aa 17&#8211;31</p><p>aa 20&#8211;29</p><p>aa 14&#8211;40</p><p>aa 14&#8211;65</p></td><td align="left" colspan="1" rowspan="1">C41 cells (Lucigen)</td><td align="left" colspan="1" rowspan="1">In vivo (mice)</td><td align="left" colspan="1" rowspan="1"><p>Protection from vaginal challenge against HPV-5/6/16/31/33/35/39/45/51/53/58</p><p>Not tested</p><p>Not tested</p><p>Not tested</p></td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR118">118</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">MS2 bacteriophage VLP</td><td align="left" colspan="1" rowspan="1">Alum hydroxide</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L2</p><p>aa 17&#8211;31</p><p>&#8201;+&#8201;</p><p>HPV-31 L2</p><p>aa 20&#8211;31</p><p>&#8201;+&#8201;</p><p>aa 69&#8211;86, 108&#8211;122 from a consensus L2 sequence</p></td><td align="left" colspan="1" rowspan="1"><p>C41 cells</p><p><italic toggle="yes">Escherichia coli</italic></p></td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1">Protection of mice against cervicovaginal infection with HPV-16/18/31/33/45/58 PsVs</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR119">119</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">MS2 Bacteriophage VLP</td><td align="left" colspan="1" rowspan="1">With and without alum hydroxide</td><td align="left" colspan="1" rowspan="1">HPV-16 L2 aa 17&#8211;31</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic> (C41)</td><td align="left" colspan="1" rowspan="1">In vivo (mice)</td><td align="left" colspan="1" rowspan="1">Spray-dried VLPs were highly immunogenic and protected mice in the genital challenge with HPV-16 PsVs</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1"><p>MS2 Bacteriophage VLP</p><p>PP7</p><p>Bacteriophage VLP</p></td><td align="left" colspan="1" rowspan="1">Incomplete Freund&#8217;s adjuvant (IFA)</td><td align="left" colspan="1" rowspan="1"><p>L2 aa 17&#8211;31 of HPV-16/31</p><p>L2 aa 17&#8211;31 of HPV-16/18</p></td><td align="left" colspan="1" rowspan="1">C41 cells (Lucigen)</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo (mice)</p></td><td align="left" colspan="1" rowspan="1"><p>Neutralized PsVs of HPV-16/18/31/45/58</p><p>Protected mice against vaginal challenge with HPV-6 PsVs</p></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR121">121</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">MS2 Bacteriophage VLP</td><td align="left" colspan="1" rowspan="1">Cholera toxin and MPL</td><td align="left" colspan="1" rowspan="1"><p>1) HPV-31 L2 aa 20&#8211;31&#8201;+&#8201;HPV-16 L2 aa 17&#8211;31</p><p>2) Consensus aa 69&#8211;86</p></td><td align="left" colspan="1" rowspan="1">C41 <italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1">In vivo (mice)</td><td align="left" colspan="1" rowspan="1"><p>Mixed VLPs contained both antigens to protect mice from PsVs;</p><p>HPV-11/16/35/39/52/53/56/58</p></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">MS2 Bacteriophage VLP</td><td align="left" colspan="1" rowspan="1">Alum</td><td align="left" colspan="1" rowspan="1"><p>1) HPV-31 L2 aa 20&#8211;31&#8201;+&#8201;HPV-16 L2 aa 17&#8211;31</p><p>2) Consensus aa 69&#8211;86</p></td><td align="left" colspan="1" rowspan="1">C41 <italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1">Mixed VLPs protected against genital infection with PsVs of HPV-5/6/51</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1"><p>Q&#946; bacteriophage VLP</p><p>PP7</p><p>bacteriophage</p><p>VLP</p></td><td align="left" colspan="1" rowspan="1">Incomplete Freund&#8217;s adjuvant</td><td align="left" colspan="1" rowspan="1"><p>HPV-16 L2 aa 34&#8211;52</p><p>aa 49&#8211;72</p><p>aa 108&#8211;120</p><p>aa 65&#8211;85</p><p>Consensus HPV-16 and &#8722;18 L2 aa 65&#8211;85</p><p>HPV-16 L2</p><p>aa 17&#8211;31</p><p>aa 51&#8211;65</p><p>aa 35&#8211;50</p></td><td align="left" colspan="1" rowspan="1">C41 <italic toggle="yes">E. coli</italic> (Lucigen)</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo</p><p><italic toggle="yes">(mice)</italic></p></td><td align="left" colspan="1" rowspan="1"><p>Protection against PsVs;</p><p>Poor protection against HPV-16</p><p>Moderate protection against HPV-16</p><p>Strong protection against HPV-16 (in vivo) HPV-6/18/31/45/58 (in vivo)</p><p>Strong protection against HPV-16</p><p>HPV-16 and &#8722;18 (in vivo)</p><p>HPV-16/18/31/45/58(in vitro)</p><p>Strong protection against HPV-16</p><p>Moderate protection against HPV-16</p><p>Poor protection against HPV-16</p></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR124">124</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Adeno-associated virus 2 VLP</td><td align="left" colspan="1" rowspan="1">Montanide ISA 51</td><td align="left" colspan="1" rowspan="1">HPV-16 and HPV-31 L2 aa 17&#8211;36</td><td align="left" colspan="1" rowspan="1">HEK 293T cells</td><td align="left" colspan="1" rowspan="1">In vitro and in vivo</td><td align="left" colspan="1" rowspan="1"><p>nAbs against HPV-16/18/31/45/52/58 PsVs in mice and rabbits</p><p>Passive transfer of sera-protected mice against vaginal challenge with HPV-16 PsVs</p></td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Adenovirus type 5 VLP</td><td align="left" colspan="1" rowspan="1">Alum and MPL</td><td align="left" colspan="1" rowspan="1">HPV-16 L2 aa 12&#8211;41</td><td align="left" colspan="1" rowspan="1">HEK 293T cells</td><td align="left" colspan="1" rowspan="1">In vitro and in vivo</td><td align="left" colspan="1" rowspan="1"><p>Protection against vaginal challenge with HPV-16</p><p>nAbs against HPV-16/73</p></td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Adenovirus type 35 VLP</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">L2 RG1 epitope from HPV-6/11/16/18/31/33/45/52/58</td><td align="left" colspan="1" rowspan="1">PER C6 cells</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">nAbs against HPV-16/18/31/59</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Hepatitis B core (HBc) VLP</td><td align="left" colspan="1" rowspan="1">Alum</td><td align="left" colspan="1" rowspan="1">aa 14&#8211;122 of HPV-16 L2</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">nAbs against HPV-16</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pyrococcus furiosus</italic> thioredoxin (trivalent-PfTrx)</td><td align="left" colspan="1" rowspan="1">Aluminum hydroxide- MPL</td><td align="left" colspan="1" rowspan="1">L2 aa 20&#8211;38 of HPV-16, HPV-31, and HPV-51</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Trichoplusia ni</italic> (TN) High Five cells</td><td align="left" colspan="1" rowspan="1"><p>In vitro (mice and guinea pigs)</p><p>In vivo</p></td><td align="left" colspan="1" rowspan="1"><p>Cross-nAbs against HPV-16/18/31/33/35/39/45/51//52/58/5968</p><p>Cross-protection against vaginal challenge with HPV-16/18/31/33/51</p></td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pf</italic>Trx&#8211;8-mer&#8211;OVX313</td><td align="left" colspan="1" rowspan="1"><p>Alum-MPL</p><p>or</p><p>glycopyranosyl lipid A</p><p>or</p><p>Army liposome formulation-alum</p></td><td align="left" colspan="1" rowspan="1">L2 aa 20&#8211;31 of HPV-6/16/18/31/33/3551/59 fused to PfTrx and OVX313</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic> BL21 cells</td><td align="left" colspan="1" rowspan="1"><p>In vitro (mice and guinea pigs)</p><p>In vivo</p></td><td align="left" colspan="1" rowspan="1"><p>Cross-nAbs in PBNA test against HPV-6/11/16/18/31/33/35/39/45/51/52/56/58/59/68/73</p><p>Passive transfer of sera-protected mice against HPV-6/11/16/18/31/33/35/39/45/56/58</p></td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1"><p>[<xref ref-type="bibr" rid="CR130">130</xref>]</p><p>[<xref ref-type="bibr" rid="CR131">131</xref>]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">P. furiosus</italic> thioredoxin fused to ferritin nanoparticles (Pf FeTrx8mer)</td><td align="left" colspan="1" rowspan="1">AddaVax</td><td align="left" colspan="1" rowspan="1">HPV-16 L2 aa 20&#8211;38 of HPV-6/16/18/31/33/35/51/59</td><td align="left" colspan="1" rowspan="1">Baculovirus-infected insect cells</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo</p></td><td align="left" colspan="1" rowspan="1"><p>nAbs titers against HPV-6/11/16/18/31/33/35/39/45/51/52/56/58/59/68/73</p><p>Passive transfer of sera-protected mice against HPV-6/11/16/18/33/35/39/45/51/56</p></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1"><p>Lipidated triple-repeat HPV-16 RG-1 epitope and a hFccRI-specific single-chain antibody fragment (H22scFv)</p><p>(LpE3H22)</p></td><td align="left" colspan="1" rowspan="1">MF59 and poly I:C</td><td align="left" colspan="1" rowspan="1">aa 17&#8211;36 of HPV-16 L2</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">E. coli</italic> (protein)</p><p>293T cells (PsVs)</p></td><td align="left" colspan="1" rowspan="1">In vivo</td><td align="left" colspan="1" rowspan="1">nAbs against HPV-2/5/6/11/16/18/31/33/35/39/45/52/58/59</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">TLR5 ligand bacterial flagellin (Fla)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">L2 aa 17&#8211;38 of HPV-6/18/31/39/52 added to HPV-16 L2 11&#8211;200 or 11&#8211;88 fused to flagellin</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo</p></td><td align="left" colspan="1" rowspan="1"><p>nAbs against HPV-6/16/18/31/45</p><p>Passive transfer of sera-protected rabbit against HPV-6/16/18/31/45/58</p></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">L2 concatemer fused to flagellin (A cL2 epitope introduced at the C-terminus of flagellin.) (Fla-5PcL2)</td><td align="left" colspan="1" rowspan="1"><p>Without adjuvant</p><p>or</p><p>alum</p><p>or</p><p>alum-MPL</p></td><td align="left" colspan="1" rowspan="1">L2 RG-1 of HPV-18/33/58/59 epitopes and HPV-16 L2 aa 11&#8211;88</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1">In vitro<italic toggle="yes">/</italic>in vivo</td><td align="left" colspan="1" rowspan="1"><p>nAbs against HPV-16/18/31/33/58</p><p>Protection of mice against vaginal challenge with HPV-5/39/58</p></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Multimeric protein</td><td align="left" colspan="1" rowspan="1">Alum</td><td align="left" colspan="1" rowspan="1"><p>L2 11&#8211;88 aa of HPV-6/16/18/31/39 (11&#8211;88&#8201;&#215;&#8201;5)</p><p>88&#8201;&#215;&#8201;8 (HPV-6/16/18/31/39/51/56/73</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic> BL21</td><td align="left" colspan="1" rowspan="1">In vivo</td><td align="left" colspan="1" rowspan="1">Protection of mice against HPV-6/16/26/31/33/35/45/51/56/58/59 challenge</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Lactobacillus casei</italic></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">HPV-16 L2 aa 1&#8211;224 fused to poly-&#947;-glutamic acid synthetase A</td><td align="left" colspan="1" rowspan="1">293T cell line</td><td align="left" colspan="1" rowspan="1">In vitro and in vivo</td><td align="left" colspan="1" rowspan="1">Oral administration protected mice against HPV-16/18/45/58</td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Fused L1&#8211;L2 genes</td><td align="left" colspan="1" rowspan="1">HEK-293 cell line</td><td align="left" colspan="1" rowspan="1"><p>In vitro</p><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1"><p>The high expression rate of recombinant L1-L2 HPV-16 DNA</p><p>Protection against C3 tumor cells</p></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">L2-based recombinant vaccine</td><td align="left" colspan="1" rowspan="1">Self-assembled peptide (OVX313) and thioredoxin</td><td align="left" colspan="1" rowspan="1">HPV-16 L2</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic> BL21</td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1">The larger antigen size correlates with enhanced B-cell induction and increased plasma half-life</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">RG2-VLP</td><td align="left" colspan="1" rowspan="1">Aluminum hydroxide</td><td align="left" colspan="1" rowspan="1">RG2</td><td align="left" colspan="1" rowspan="1">Cottontail rabbit papillomavirus (CRPV) quasivirus</td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1"><p>Robust L2-specific antibody titers and protection against &#946;-type HPV5</p><p>Similar HPV16- and HPV18-specific neutralizing Ab responses between RG2-VLP- and Gardasil&#174;9 groups</p></td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">MS2-L2 VLPs</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">MS2-31L2/16L2 VLPs and MS2-consL2 (69&#8211;86)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1">Constant antibody titer against HPV16 L2 (aa 17&#8211;31) and HPV31 L2 (aa 17&#8211;31) peptides</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">RG1-VLP</td><td align="left" colspan="1" rowspan="1">Aluminum hydroxide or poly[di (carboxylatoethylphenoxy) phosphazene] (PCEP)</td><td align="left" colspan="1" rowspan="1"><p>HPV16-L1</p><p>L2 RG1</p></td><td align="left" colspan="1" rowspan="1">293-TTF cells</td><td align="left" colspan="1" rowspan="1"><p>In vivo</p><p>(mice)</p></td><td align="left" colspan="1" rowspan="1"><p>Cross-neutralization of pseudovirion types HPV18 and HPV39</p><p>Sufficient level of Ab titer after two doses of vaccine with PCEP</p></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR140">140</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">HPV16L2-N200 (first 200 aa of L2) HPV16L2-N88 as fused or mixed with Tat-protein transduction domain (PTD) as a CPP</td><td align="left" colspan="1" rowspan="1">Freund's adjuvant</td><td align="left" colspan="1" rowspan="1">HPV16-L2</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic></td><td align="left" colspan="1" rowspan="1">In vivo (mice)</td><td align="left" colspan="1" rowspan="1">Increased titer of anti-HPV16L2 total antibodies and neutralizing antibodies for HPV16 and other HR-HPVs (HPV16, 18, 31, 45, and 58) following vaccination with fused PTD-L2-N200</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr></tbody></table><table-wrap-foot><p>HPV: Human papillomavirus; HR-HPV: high-risk HPV; LR-HPV: low-risk HPV; CPP: cell-penetrating peptide; MPL: Monophosphoryl Lipid A; nAbs: neutralizing antibodies; PBNA: pseudovirion-based neutralization assay; PsVs: Pseudovirions</p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Clinical trials of L2-based vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Vaccine</th><th align="left" colspan="1" rowspan="1">Class</th><th align="left" colspan="1" rowspan="1">Phase</th><th align="left" colspan="1" rowspan="1">Title of trial</th><th align="left" colspan="1" rowspan="1">Target disease/ HPV type</th><th align="left" colspan="1" rowspan="1">Administration route</th><th align="left" colspan="1" rowspan="1">Outcome measures</th><th align="left" colspan="1" rowspan="1">NCT</th><th align="left" colspan="1" rowspan="1">Sponsor</th><th align="left" colspan="1" rowspan="1">Status</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Adeno-associated VLPs (AAVLP)</td><td align="left" colspan="1" rowspan="1">VLP-based vaccine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">A study of safety, tolerability, and immunogenicity of HPV-L2 vaccine in healthy adult male and female subjects</td><td align="left" colspan="1" rowspan="1">Antibodies against HPV-6/11/16/18</td><td align="left" colspan="1" rowspan="1">Intramuscular (IM)</td><td align="left" colspan="1" rowspan="1"><p>1. Percentage of local/ general symptoms</p><p>2. Percentage of adverse events</p><p>3. Vital signs</p></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03929172">NCT03929172</ext-link></td><td align="left" colspan="1" rowspan="1">2A Pharma AB</td><td align="left" colspan="1" rowspan="1"><p>Completed/</p><p>Last updated in 2020</p></td></tr></tbody></table></table-wrap></p><sec id="Sec19"><title>VLP-based second-generation HPV vaccines</title><p id="Par36">VLPs generated from the capsids of different viruses can be used as carriers to present L2 epitopes [<xref ref-type="bibr" rid="CR142">142</xref>].</p><sec id="Sec20"><title>Papillomavirus VLPs</title><p id="Par37">Using L2 epitopes on L1 VLPs as scaffolds is a promising approach for achieving broader efficacy against diverse HPV types. Numerous studies have focused on this strategy [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par38">Inserting aa 17&#8211;36 of HPV-16 L2 (a frequently reported epitope on L2, also called the RG1 epitope) into the DE-surface loop of the HPV-16-VLP resulted in developing a potent chimeric HPV vaccine. Schellenbacher and colleagues reported that RG1-VLP vaccination with alum-MPL (aluminum hydroxide plus 3-O-desacyl-4&#8242;-monophosphoryl lipid A) elicited robust immune responses against L2 and provided protection against multiple types of cutaneous and mucosal HPV infections. They observed protection against mucosal HR-HPV types 16/18/45/37/33/52/58/35/39/51/59/68/73/26/69/34/70, LR-HPV types 6/11/32/40, and cutaneous HPV types 2/3/27/76 in a pseudovirion-based neutralization assay (PBNA). Furthermore, nAbs against mucosal HR-HPV-16/18/45/31/33/52/58/35/39/51/59/68/56/73/26/53/66/34 and LR-HPVs 6/43/44 were induced in rabbits and mice. Furthermore, the vaccine also stimulated robust cytotoxic T-cell responses with protection lasting one year. RG1-VLPs were produced under Current Good Manufacturing Practice (CGMP) to initiate a Phase 1 clinical trial, as noted in their 2013 publication [<xref ref-type="bibr" rid="CR108">108</xref>]. However, no further updates regarding this project have been reported. Notably, chimeric VLPs displaying L2 epitopes can be generated with minor modifications to the existing approved HPV vaccines [<xref ref-type="bibr" rid="CR106">106</xref>].</p></sec><sec id="Sec21"><title>Bacteriophage VLPs</title><p id="Par39">Bacteriophages can serve as efficient platforms for presenting various antigens, such as L2 epitopes, to enhance the immune response. They can be produced in a bacterial system, such as <italic toggle="yes">E. coli</italic>, at a low cost and with a straightforward purification process. This platform may also act as a natural adjuvant, as encapsidated bacteriophage single-stranded (ss) RNAs can activate TLR-7 and &#8722;8 [<xref ref-type="bibr" rid="CR106">106</xref>]. Pseudomonas phage 7 (PP7) [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>] and <italic toggle="yes">Emesvirus zinderi</italic> (MS2) [<xref ref-type="bibr" rid="CR118">118</xref>] bacteriophages were used to display L2 epitopes. PP7 VLPs displaying the aa 17&#8211;31 of L2 induced cross-protection against HPV-16 and the heterologous HPV pseudovirion type HPV-45 following IM injection in mice [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par40">Inserting the aa 17&#8211;31 L2 epitope at the N-terminus of the MS2 coat protein VLPs could induce significant protection against several heterologous HPV types in vivo. Cross-protection was observed following intravaginal challenge with mucosal HR-HPV-16/31/33/35/39/45/51/53/58 and LR-HPV-6 or intradermal challenge with beta-HPV5 in mouse models [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. This candidate vaccine demonstrated high immunogenicity in mice, both with and without the alum adjuvant; and a single dose of the MS2-16 L2 VLPs vaccine elicited a robust immune response lasting more than 18&#160;months. This study highlighted that in addition to the previously mentioned advantages of bacteriophage VLP display, spray drying technology allows VLPs to maintain their immunogenicity and stability for over one month at room temperature or 37&#160;&#176;C [<xref ref-type="bibr" rid="CR120">120</xref>]. Importantly, Peabody&#8217;s experiments indicated that spray-dried MS2-16 L2 VLPs exhibited thermostability for 34&#160;months at room temperature and 14&#160;months at 37&#160;&#176;C, allowing the vaccine to be immunogenic and effective in mice [<xref ref-type="bibr" rid="CR71">71</xref>]. However, Agilvax&#174; has ceased the development of the MS2 VLP-16 L2 vaccine technology following cGMP development [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec22"><title>Adeno-associated VLPs (AAVLPs)</title><p id="Par41">Adeno-associated viruses (AAV) are nonpathogenic ss DNA viruses that can be used for vaccine delivery. They exhibit stability across a wide range of pH and temperatures. Their capsid comprises 60 protein subunits, including virus protein 1 (VP1), VP2, and VP3, which can serve as peptide scaffolds in vaccine development. Adeno-associated VLPs (AAVLPs) were created by the double insertion of the RG1 epitope (aa 17&#8211;36) of HPV-16 and HPV-31 into the VP3 of AAV2 capsid. The vaccine demonstrated stability at various pH values and temperatures. AAVLP (HPV-16 and &#8722;31 L2) used with montanide adjuvant induced cross-nAbs against HPV-16/18/31/45/52/58 and bovine papillomavirus type 1 in mice. Furthermore, the immunogenicity of the lyophilized particles of AAVLP (HPV-16 and &#8722;31 L2) was maintained. Lyophilization can effectively address cold-chain limitations [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p id="Par42">Jagu et al. investigated AAVLP (containing HPV-16 and &#8722;31 L2) vaccines with three different adjuvant systems: alum only, alum combined with MPL, and RIBI adjuvants. The administration of this candidate vaccine to mice without any adjuvants did not elicit an immune response against L2. In contrast, the alum adjuvant provided strong and durable immune protection that lasted over three months. The concurrent use of MPL and RIBI enhanced antibody titers. Furthermore, AAVLP (HPV-16/31 L2) alone, with alum&#8201;&#177;&#8201;MPL or RIBI adjuvants in rabbits, demonstrated potential effectiveness against HPV-16/31/35/39/45/58/59, with protective effects detectable 6&#8211;12&#160;months post-immunization [<xref ref-type="bibr" rid="CR145">145</xref>]. 2A Pharma AB has initiated a Phase 1 clinical trial for this candidate vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03929172">NCT03929172</ext-link>, last updated in 2020).</p></sec><sec id="Sec23"><title>Adenovirus VLPs</title><p id="Par43">Adenovirus 5 (ad5) has a major antigenic capsid protein, hexon, which comprises nine hypervariable regions (HVR). The insertion or substitution of aa 12&#8211;41 of L2 HPV-16 within HVR1 or HVR5 resulted in the creation of recombinant ad5. The specific L2 response to the recombinant ad5 was initially weak; however, the incorporation of alum and MPL adjuvants augmented antibody titers. NAb titers and protection against HPV-16 and &#8722;73 were observed in mice but not against HPV-56 [<xref ref-type="bibr" rid="CR126">126</xref>]. To broaden vaccine coverage, concatemers of the L2 RG1 epitopes from HPV-6/11/16/18/31/33/45/52 and 58 were inserted into the C-terminus of protein IX of adenovirus 35. The HAdV35 pIX-L2 (human adenovirus 35 protein IX) without an adjuvant elicited robust immune responses and nAbs against HPV-16/18/31/59 [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>].</p></sec><sec id="Sec24"><title>Tobacco mosaic virus display</title><p id="Par44">Tobacco mosaic virus (TMV) was employed as a scaffold to present L2 epitopes [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>]. Palmer et al. used recombinant TMV as a vector to display aa 94&#8211;122 of the L2 of rabbit oral papillomavirus (ROPV) and Cottontail rabbit papillomavirus (CRPV) with the RIBI adjuvant. The CRPV rTMVs alone or with ROPV demonstrated strong immunogenicity in rabbits against the CRPV challenge; however, ROPV L2 rTMVs elicited a weak immune response against the CRPV challenge. The advantages of these scaffolds include ease of production and low purification costs [<xref ref-type="bibr" rid="CR147">147</xref>].</p></sec><sec id="Sec25"><title>Others</title><p id="Par45">The hepatitis B virus core (HBc) was utilized as a VLP carrying aa 14&#8211;122 of the HPV-16 L2. HBc VLPs resulted in elevated titers of L2 antibodies and nAbs against HPV-16 in mice [<xref ref-type="bibr" rid="CR128">128</xref>]. Other studies have used recombinant potato virus VLPs [<xref ref-type="bibr" rid="CR148">148</xref>] or grapevine fanleaf virus (GFLV) VLPs [<xref ref-type="bibr" rid="CR149">149</xref>] to deliver L2 epitopes.</p></sec></sec><sec id="Sec26"><title>Peptide vaccines/recombinant L2 peptides</title><p id="Par46">The intranasal administration of L2 aa 108&#8211;120, which contains cross-neutralizing epitopes without adjuvants, induced the mucosal (mainly IgA) and systemic (mostly IgG) antibodies in mice. A high dose of this candidate vaccine was tolerable in humans in a Phase 1 clinical trial. Neutralizing activities against HPV-16 and &#8722;52 were found in the sera of four patients (out of five). Based on the outcomes, L2 could be bound to immunostimulant agents or be designed as a concatemer of peptides to enhance immune responses [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR150">150</xref>].</p><sec id="Sec27"><title>Vaccines consisting of epitope peptides fused to immunostimulants</title><p id="Par47">L2 peptides fused to different immunostimulatory peptides, such as thioredoxin, and some TLRs (including TLR-2, TLR-4, and TLR-5 agonists) have been investigated in several studies. Thioredoxin is an immunostimulatory agent obtained from different bacteria, which serves as a peptide scaffold. Incorporating HPV-16 L2 aa 20&#8211;38 into bacterial thioredoxin provoked immune responses in mice by inducing cross-nAbs against HPV-16/18/31/45/58 [<xref ref-type="bibr" rid="CR151">151</xref>]. The incorporation of aa 20&#8211;38 L2 of HPV-16/31/51 into <italic toggle="yes">Pyrococcus furiosus</italic> thioredoxin (PfTrx) adjuvanted with aluminum hydroxide and MPL induced cross-nAbs against 12 of the 13 oncogenic HPV types (HPV-16/18/45/31/33/52/58/35/59/51/39/68) in mice and guinea pigs. Notably, the trivalent PfTrx L2 formulation demonstrated thermostability, which could mitigate cold storage challenges and also accelerate purification processes [<xref ref-type="bibr" rid="CR129">129</xref>].</p><p id="Par48">To enhance the immunogenicity of this strategy, Spagnoli et al. developed single peptides containing eight distinct epitopes of L2 (aa 20&#8211;38) bound to a bacterial thioredoxin carrier. To further enhance immunogenicity, these thioredoxin L2 polytopes were fused to OVX313 (a heptamerization domain). OVX313, a synthetic self-assembling polypeptide, is an IMX313 derivative. Both of these molecules were developed by the Osivax&#174; Company from C4-binding protein (C4bp), a complement inhibitor [<xref ref-type="bibr" rid="CR131">131</xref>]. C4bp naturally inhibits the classical and lectin pathways of the complement system. OVX313, which differs from human or murine C4bp due to some modifications, was shown to increase B-cell and T-cell responses; though the mechanism is not well understood [<xref ref-type="bibr" rid="CR130">130</xref>]. PfTrx-OVX313 nanoparticles could be introduced as third-generation HPV vaccines, and this L2 scaffold was highly immunogenic. It could evoke nAbs against 10 HPV types in mice [<xref ref-type="bibr" rid="CR131">131</xref>]. In another study by Pouyanfard et al., PfTrx&#8211;11-mer&#8211;OVX313, which contained aa 20&#8211;38 L2 of 11 HPV types, neutralized 14 types of oncogenic HPVs, HPV-6 and &#8722;11 (which are LR-HPVs), and some cutaneous HPVs [<xref ref-type="bibr" rid="CR130">130</xref>]. The PANHPVAX (Trx-L2m8mer-OVX313 antigen) candidate vaccine, formulated with the cyclic di-adenosine monophosphate (cdA) adjuvant, has entered a Phase 1 clinical trial as of 2022 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05208710">NCT05208710</ext-link>) [<xref ref-type="bibr" rid="CR152">152</xref>].</p><p id="Par49">Another approach to enhance L2 epitope immunogenicity is to fuse it with a TLR agonist as an immunostimulant. An HPV lipopeptide vaccine was made from the RG1 epitope of L2 HPV-16 in combination with a T-helper epitope (P25) and the TLR2 ligand dipalmitoyl-S-glyceryl cysteine (P2C). The administration of P25-P2C-HPV lipopeptides in mice, either intranasally or subcutaneously, induced serum-nAbs that neutralized HPV-16 pseudovirions in addition to oncogenic cutaneous (HPV-5 and BPV1 [bovine papillomavirus 1]) and genital (HPV-18 and &#8722;45) types [<xref ref-type="bibr" rid="CR153">153</xref>].</p><p id="Par50">Several studies have used flagellin, a TLR5 ligand, as a vaccine adjuvant. Klannin and colleagues reported that the flagellin-L2 multimer, even without additional adjuvants, demonstrated promising results because it could act as a self-adjuvant antigen. Various studies have been conducted on multimer and monomer L2 residues. Consequently, adding aa 17&#8211;38 L2 of HPV-6/18/31/39/52 to aa 11&#8211;88 or aa 11&#8211;200 on L2 HPV-16 fused to flagellin caused robust and extensive protection lasting over one year [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. Another recombinant protein was designed by Zhang et al. and contains the HPV-18/33/58/59 RG1 epitopes, the HPV-16 aa 11&#8211;88, and the L2 epitope (aa 65&#8211;85) fused to flagellin to provoke the immune system. Both subcutaneous and intranasal administration in mice elicited cross-nAbs against HPV-16/18/31/33/58 in mucosal secretions and protection against vaginal challenge by HPV-39/58/5 [<xref ref-type="bibr" rid="CR135">135</xref>]. A multiepitope peptide vaccine designed in silico by our team, which incorporated flagellin and a synthetic TLR4 agonist [<xref ref-type="bibr" rid="CR45">45</xref>], also induced several cytokines in mice, which could lead to humoral and cellular immune responses with a more Th-1 favored pattern [<xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par51">An alternative approach was investigated in a study by Zeng et al. using a cell-penetrating peptide (CPP) to facilitate the intracellular delivery of the vaccine [<xref ref-type="bibr" rid="CR156">156</xref>]. The protein transduction domain (PTD) of the Tat protein of human immunodeficiency virus (HIV) was used as a CPP, which was either mixed or fused with two peptides from the N&#8209;terminal of HPV16 L2. The fusion form of the vaccine showed increased humoral responses and cross-protection [<xref ref-type="bibr" rid="CR157">157</xref>].</p></sec><sec id="Sec28"><title>Alternative approaches focusing on nanovaccines</title><p id="Par52">Different vaccine development research has shown the great potential of nanovaccines and related delivery systems. The resemblance of nanovaccines to pathogens regarding their size is the main reason for their significant advantages as vaccines [<xref ref-type="bibr" rid="CR9">9</xref>]. VLPs and some other well-known platforms could also fall into this category. However, there are other approaches not employed for HPV vaccines that may deserve exploring.</p><p id="Par53">Exosomes, as natural nanovesicles responsible for the extracellular transfer of various materials (such as proteins and nucleic acids) within the body [<xref ref-type="bibr" rid="CR158">158</xref>], could be used for vaccine delivery [<xref ref-type="bibr" rid="CR9">9</xref>]. Exosomes have been investigated for a therapeutic HPV vaccine before [<xref ref-type="bibr" rid="CR159">159</xref>], but not for prophylaxis.&#160;Alternative platforms such as self-assembled peptide nanoparticles, liposomes, and other structures found elsewhere [<xref ref-type="bibr" rid="CR142">142</xref>], could also be investigated for HPV.</p></sec><sec id="Sec29"><title>Multimer or synthetic peptides</title><p id="Par54">The use of concatemeric (multimeric) peptides has broadened protection against diverse HPVs. Generally, due to the low immunogenicity of multimeric peptides, they should be used in conjunction with potent adjuvants. Jagu et al. performed a series of studies on concatenated multitype L2 peptides [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR160">160</xref>&#8211;<xref ref-type="bibr" rid="CR162">162</xref>]. Bravovax&#174; is currently developing the most effective structure identified in these experiments. They designed a concatemeric peptide by fusing L2 aa 11&#8211;88 of HPV-6/16/18/31/39 (11&#8211;88&#8201;&#215;&#8201;5) and 11&#8211;88&#8201;&#215;&#8201;8, adding HPV-51/56/73 to the previous types along with alum adjuvant. Antibodies elicited by this candidate vaccine protected mice against HPV-6/16/26/31/33/35/45/51/56/58/59 challenges. Importantly, since concatemeric peptides can be produced in bacteria, their production costs are lower than those of licensed vaccines, such as Gardasil&#174;. Additionally, these concatemeric vaccines produced long-lasting (lasting more than one year) and broader immunity [<xref ref-type="bibr" rid="CR136">136</xref>].</p></sec></sec><sec id="Sec30"><title>Recombinant bacteria</title><p id="Par55">Recombinant bacteria can also be used to present the L2 protein. Yoon et al. used <italic toggle="yes">Lactobacillus casei</italic> to display HPV-16 L2 aa 1&#8211;224 fused to poly-&#947;-glutamic acid synthetase A on bacterial surfaces. Oral administration of this vaccine in mice resulted in the production of nAbs against HPV-16/18/45/58. <italic toggle="yes">L. casei</italic>, a member of the human gut microbiota, is considered safe. Additionally, the low cost of mass production is an advantage of this platform. The oral route could be convenient and especially beneficial in remote areas in countries with limited access to healthcare services, such as some African countries [<xref ref-type="bibr" rid="CR137">137</xref>].</p></sec><sec id="Sec31"><title>DNA and mRNA&#160;vaccines</title><p id="Par56">DNA vaccines are appealing platforms due to their safety, stability, and low production cost. They also effectively elicit cytotoxic T cells and humoral responses. One study produced an L2 DNA vaccine by cloning L2 HPV-16 into a pTH vector. While L2-specific antibodies and cell-mediated responses were detected in mice, antibody titers were low, and the antibodies did not show neutralizing activity [<xref ref-type="bibr" rid="CR163">163</xref>]. Namvar et al. reported that recombinant L1-L2 HPV-16 DNA expression in human embryonic kidney cells (HEK-293) was greater than in the L1 DNA construct because L2 facilitates DNA delivery and transfer across the cell barrier [<xref ref-type="bibr" rid="CR164">164</xref>]. Furthermore, L1&#8210;L2 HPV-16 DNA constructs without adjuvants elicited effective and protective immune responses. Protection against C3 tumor cells has also been observed in mice [<xref ref-type="bibr" rid="CR138">138</xref>]. Additionally, mRNA vaccines initially developed for COVID-19 and now under investigation as novel platforms for many diseases, could serve as safer alternatives. mRNA vaccines have been investigated as preventive HPV vaccines; however, to our knowledge, they have not yet been studied for preventive purposes. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> summarizes all the investigated prophylactic HPV vaccine platforms and their consequent immune responses.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Schematic representation of all investigated prophylactic HPV vaccine platforms for prophylaxis and their produced immune response</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13027_2025_643_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec32"><title>Routes of administration and dosage forms</title><p id="Par57">HPV vaccines are administered via IM injections, similar to many other vaccines. They are relatively easy to apply, create a reservoir of immunogenic substances, and have been shown to be sufficiently safe [<xref ref-type="bibr" rid="CR7">7</xref>]. However, the demand for more convenient routes remains undeniable.</p><p id="Par58">Electroporation can increase the injection efficiency. Electric pulses induce the breakdown of the keratinocyte structure in the skin. It facilitates the transport of immunogenic substances through the cell membrane, allowing a higher number of antigens to encounter immune compartments. For example, a DNA-based therapeutic vaccine (MEDI0457) targeting E6 and E7 of HPV-16 and &#8722;18, was investigated in a Phase 1 clinical trial using an electroporation device, called CELLECTRA&#174;. After each vaccine dose, electroporation with CELLECTRA&#174; was performed. Although no comparison was made between the use and nonuse of CELLECTRA&#174;, the regimen was deemed safe and well-tolerated [<xref ref-type="bibr" rid="CR165">165</xref>]. The transdermal route is another newly suggested route for HPV vaccine administration. Due to the abundance of immune cells, including Langerhans cells, T cells, and dermal dendritic cells, transdermal delivery, similar to intradermal delivery, effectively facilitates the interaction between immunogenic substances and immune cells. For example, microparticles containing HPV16 L1&#8201;+&#8201;L2 VLPs were prepared and loaded onto an AdminPatch&#174;. The administration of this patch to BALB/c mice induced a robust immune response, as evidenced by elevated IgG titers and immune cell populations (CD4&#8201;+&#8201;, CD8&#8201;+&#8201;, CD27&#8201;+&#8201;, CD45R&#8201;+&#8201;, and CD62L&#8201;+&#8201;cells). This approach may offer a promising alternative for less invasive, efficient, and pain-free vaccine administration [<xref ref-type="bibr" rid="CR166">166</xref>].The intranasal and oral routes are also being evaluated for different vaccines due to their convenient usage and potential to induce mucosal immunity. These formulations could be specifically promising for first-line protection against HPV infection. Oral vaccines are of particular interest, especially in the form of particulate nanostructures. These particulate systems can protect antigen integrity under enzymatic and acidic conditions in the stomach and intestine. Moreover, nanoparticles can cross-present antigens to induce T-cell responses and usually do not require further adjuvants.</p><p id="Par59">Current vaccines mostly employ adjuvants as essential formulation ingredients. For example, the Cervarix&#174; formulation contains both Al2O3 and ASO4 (3-O-desacyl-4-monophosphoryl lipid A) as adjuvants, which help induce humoral immunity. However, the main immunogenicity of VLP vaccines, including Cervarix&#174;, is attributed to the repetitive structure of epitopes on VLPs, which facilitates cross-linking of B cell receptors, inducing B cell responses, leading to the induction of nAbs following vaccination. Moreover, the uptake of VLPs by antigen-presenting cells (APCs) initiates the activation of adaptive immunity [<xref ref-type="bibr" rid="CR167">167</xref>]. VLP structures could also be considered nanostructures [<xref ref-type="bibr" rid="CR142">142</xref>]. When a vaccine is administered orally, antigens or antigen-containing particles are phagocytosed by M cells in Peyer&#8217;s patches in the small intestine (aggregations of lymphoid tissue in the lowest portion of the small intestine) [<xref ref-type="bibr" rid="CR168">168</xref>]. These cells deliver antigens to lymphoid tissues and resident macrophages and serve as APCs. This can induce mucosal immune responses [<xref ref-type="bibr" rid="CR167">167</xref>]. Fraillery et al. examined the oral administration of recombinant <italic toggle="yes">Salmonella enterica</italic> expressing the L1 protein of HPV-16 and &#8722;18, which evoked a strong immune response [<xref ref-type="bibr" rid="CR169">169</xref>].</p><p id="Par60">The intranasal route represents a promising method for administering HPV vaccines, as it can induce a proper mucosal immune response. Mucosal immune activation is particularly significant, given that HPV infect and persists in epithelial cells and mucosa. A recombinant adeno-associated virus (AAV) expressing the HPV-16 L1 antigen was designed and intranasally administered to mice and rhesus macaques. Robust immune induction was observed without the use of adjuvants. AAVs can release antigens in the nasal mucosa for an extended duration. Although it supports the induction of a long-lasting immune response (remaining anti-L1 antibody titer 60 days after intranasal administration in mice), it may also cause T-cell exhaustion. Moreover, AAVs exhibit physical stability during lyophilization [<xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR171">171</xref>]. Finally, a combined prophylactic and therapeutic intranasal vaccine was designed using recombinant AAV-5 and &#8722;9 expressing the L1 and E7 proteins of HPV-16. This intranasal vaccine produced a stronger humoral and cellular response than HPV-16 L1/E7 VLPs. The potential of lyophilization as an alternative to reduce added costs and simplify storage and distribution is promising for the future of vaccine administration [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>].</p></sec></sec><sec id="Sec33"><title>Access expansion and other strategies to further benefit from current HPV vaccines</title><p id="Par61">The promising outcomes of vaccination programs in certain countries demonstrate that CxCa is preventable, highlighting the need for global initiatives to implement more robust strategies aimed at eliminating this cancer and other HPV-related tumors. Thus, various plans that support the acceleration of vaccination among different populations are critical. This could include improving national immunization programs in some countries, adding HPV vaccines to national childhood immunization programs [<xref ref-type="bibr" rid="CR174">174</xref>], or even combining them with another essential vaccine and gender-neutral vaccination, which could prevent infections in women and men through herd immunity [<xref ref-type="bibr" rid="CR175">175</xref>]. These approaches have been discussed elsewhere [<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]. Nevertheless, developing HPV prophylactic vaccines with broader coverage, improved accessibility, and reduced costs represents a significant advancement that could raise the bar in this field.</p></sec></sec><sec id="Sec34"><title>Conclusion and perspectives</title><p id="Par62">Given the confirmed role of HPV in CxCa, immunization against HPV is recommended as a key preventive strategy. While the effectiveness of current prophylactic L1-based VLP vaccines against HPV has been demonstrated over nearly two decades, there is still a demand for novel vaccines with broader coverage, improved affordability, and easier transportation and storage conditions. Therefore, research on other platforms is ongoing, primarily summarized in this review. Though the vast volume of studies on HPV prophylactic vaccines over many years is a barrier to mentioning all the published works, we tried to cover the main approaches and steps undertaken to date.</p><p id="Par63">Since the success of marketed vaccines has raised expectations for newcomers, no other studied approach has outperformed in clinical trials yet. In parallel with research on alternative vaccine platforms, the production of more affordable L1 VLP vaccines in countries such as China and India&#8212;specifically Cecolin&#174;, Walrinvax&#174;, and Cervavac&#174;&#8212;is actively addressing issues related to supply and affordability. WHO has already prequalified Cecolin&#174; and Walrinvax&#174;. The recombinant production of Cecolin&#174;, a vaccine with comparable efficacy to Cervarix&#174;, in the <italic toggle="yes">E. coli</italic> host represents significant progress in HPV vaccine production. However, similar to previous L1 protein-based vaccines, it provides limited cross-protection against different HPV types and requires cold-chain maintenance. Overall, the recent biosimilar HPV vaccines produced in China and India have characteristics nearly identical to the original products regarding dosage, route of administration, and storage conditions. Their primary advantage lies in their lower prices, which can significantly enhance HPV vaccination rates by reducing financial barriers, especially in developing countries. While these biosimilars are beneficial, developing alternative novel vaccine platforms and formulations may offer a more comprehensive solution in the long run.</p><p id="Par64">Vaccines containing L2 peptides seem promising candidates due to their broader coverage across different virus types and easier and lower-cost production. However, their linear structure results in decreased immunogenicity, highlighting the role of adjuvants or carrier systems in vaccine formulations. Despite extensive research on L2-based vaccines at preclinical stages (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>), only one vaccine containing AAVLPs has progressed to clinical trials (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par65">Consequently, linear L2-based protein vaccines seem far from achieving optimal efficacy unless combined with other immune-enhancing strategies. Employing scaffolds, carriers, and nanotechnological approaches, as well as combining several mentioned approaches may improve outcomes in the future. Using L2 antigens as mRNA or DNA vaccine platforms represents a potential strategy to enhance antigenicity while reducing type-specificity, warranting further investigation.</p><p id="Par66">On the other hand, alternative routes of administration, such as oral or intranasal vaccines, could facilitate administration and improve access, particularly in remote areas and underdeveloped countries, thereby enhancing global vaccination coverage.</p><p id="Par67">Combining L2 with E6, E7, or E5 viral proteins to confer both prophylactic and therapeutic capabilities can benefit more people worldwide. Although these vaccines are not yet sufficiently efficient, such approaches deserve further investigation and may open new avenues for future research.Overall, the fight against CxCa continues. Developing novel HPV vaccines, along with improved vaccination programs at the global level, is essential to achieve better control of HPV-induced CxCa and other malignancies.</p></sec></body><back><fn-group><fn><p>Sogand Amiri, Shiva Rasekh are Co-first authors.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>S.A., Sh.R., SMI.M., N.S., SA.F., and Sh.N. performed the searches and wrote the manuscript. SMI.M. coordinated the project and helped revise and edit the manuscript. A.B. helped write and revise the manuscript. M.N. conceived the idea, designed and supervised the project, and revised and edited the manuscript. All the authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funds were received for this research.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par68">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par69">All the authors provided their consent to publish this review article.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#8211;63.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Cervical Cancer, World Health Organization<italic toggle="yes">, </italic>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/cervical-cancer">https://www.who.int/news-room/fact-sheets/detail/cervical-cancer</ext-link><italic toggle="yes">, </italic>Access Date: August 2024.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guida</surname><given-names>F</given-names></name><etal/></person-group><article-title>Global and regional estimates of orphans attributed to maternal cancer mortality in 2020</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>12</issue><fpage>2563</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02109-2</pub-id><pub-id pub-id-type="pmid">36404355</pub-id><pub-id pub-id-type="pmcid">PMC9676732</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Guida F, et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med. 2022;28(12):2563&#8211;72.<pub-id pub-id-type="pmid">36404355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02109-2</pub-id><pub-id pub-id-type="pmcid">PMC9676732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosbie</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Human papillomavirus and cervical cancer</article-title><source>The Lancet</source><year>2013</year><volume>382</volume><issue>9895</issue><fpage>889</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60022-7</pub-id><pub-id pub-id-type="pmid">23618600</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Crosbie EJ, et al. Human papillomavirus and cervical cancer. The Lancet. 2013;382(9895):889&#8211;99.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)60022-7</pub-id><pub-id pub-id-type="pmid">23618600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelzle</surname><given-names>D</given-names></name><etal/></person-group><article-title>Estimates of the global burden of cervical cancer associated with HIV</article-title><source>Lancet Glob Health</source><year>2021</year><volume>9</volume><issue>2</issue><fpage>e161</fpage><lpage>e169</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30459-9</pub-id><pub-id pub-id-type="pmid">33212031</pub-id><pub-id pub-id-type="pmcid">PMC7815633</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Stelzle D, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161&#8211;9.<pub-id pub-id-type="pmid">33212031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(20)30459-9</pub-id><pub-id pub-id-type="pmcid">PMC7815633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petca</surname><given-names>A</given-names></name><etal/></person-group><article-title>Non-sexual HPV transmission and role of vaccination for a better future</article-title><source>Exp Ther Med</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>1</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.3892/etm.2020.9316</pub-id><pub-id pub-id-type="pmid">33101476</pub-id><pub-id pub-id-type="pmcid">PMC7579832</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Petca A, et al. Non-sexual HPV transmission and role of vaccination for a better future. Exp Ther Med. 2020;20(6):1&#8211;1.<pub-id pub-id-type="pmid">33101476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2020.9316</pub-id><pub-id pub-id-type="pmcid">PMC7579832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>I</given-names></name><etal/></person-group><article-title>human papilloma virus: an unraveled enigma of universal burden of malignancies</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><issue>4</issue><fpage>564</fpage><pub-id pub-id-type="doi">10.3390/pathogens12040564</pub-id><pub-id pub-id-type="pmid">37111450</pub-id><pub-id pub-id-type="pmcid">PMC10146077</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Khan I, et al. human papilloma virus: an unraveled enigma of universal burden of malignancies. Pathogens. 2023;12(4):564.<pub-id pub-id-type="pmid">37111450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens12040564</pub-id><pub-id pub-id-type="pmcid">PMC10146077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garland</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience</article-title><source>Rev Infect Dis</source><year>2016</year><volume>63</volume><issue>4</issue><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw354</pub-id><pub-id pub-id-type="pmcid">PMC4967609</pub-id><pub-id pub-id-type="pmid">27230391</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Garland SM, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Rev Infect Dis. 2016;63(4):519&#8211;27.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw354</pub-id><pub-id pub-id-type="pmcid">PMC4967609</pub-id><pub-id pub-id-type="pmid">27230391</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><name name-style="western"><surname>Vakili</surname><given-names>B</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N</given-names></name></person-group><article-title>Exosome-based vaccines and their position in next generation vaccines</article-title><source>Int Immunopharmacol</source><year>2022</year><volume>113</volume><fpage>109265</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2022.109265</pub-id><pub-id pub-id-type="pmid">36252477</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Negahdaripour M, Vakili B, Nezafat N. Exosome-based vaccines and their position in next generation vaccines. Int Immunopharmacol. 2022;113: 109265.<pub-id pub-id-type="pmid">36252477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2022.109265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>L</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name></person-group><article-title>Virus-like particle-based L2 vaccines against HPVs: Where are we today?</article-title><source>Viruses</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/v12010018</pub-id><pub-id pub-id-type="pmcid">PMC7019592</pub-id><pub-id pub-id-type="pmid">31877975</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Yadav R, Zhai L, Tumban E. Virus-like particle-based L2 vaccines against HPVs: Where are we today? Viruses. 2020;12(1):18.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12010018</pub-id><pub-id pub-id-type="pmcid">PMC7019592</pub-id><pub-id pub-id-type="pmid">31877975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amboree</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000&#8211;2019</article-title><source>Int J Cancer</source><year>2024</year><volume>154</volume><issue>9</issue><fpage>1549</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1002/ijc.34860</pub-id><pub-id pub-id-type="pmid">38270521</pub-id><pub-id pub-id-type="pmcid">PMC11410343</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Amboree TL, et al. Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000&#8211;2019. Int J Cancer. 2024;154(9):1549&#8211;55.<pub-id pub-id-type="pmid">38270521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34860</pub-id><pub-id pub-id-type="pmcid">PMC11410343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">World Health Organization, Human Papillomavirus (HPV), Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/human-papillomavirus">https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/human-papillomavirus</ext-link><italic toggle="yes">,</italic> 2022.</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zur Hausen</surname><given-names>H</given-names></name></person-group><article-title>Papillomaviruses and cancer: from basic studies to clinical application</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><issue>5</issue><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nrc798</pub-id><pub-id pub-id-type="pmid">12044010</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342&#8211;50.<pub-id pub-id-type="pmid">12044010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc798</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Perspectives for therapeutic HPV vaccine development</article-title><source>J Biomed Sci</source><year>2016</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s12929-016-0293-9</pub-id><pub-id pub-id-type="pmid">27809842</pub-id><pub-id pub-id-type="pmcid">PMC5096309</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yang A, et al. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):1&#8211;19.<pub-id pub-id-type="pmid">27809842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-016-0293-9</pub-id><pub-id pub-id-type="pmcid">PMC5096309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiffman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Carcinogenic human papillomavirus infection</article-title><source>Nat Rev Dis Primers</source><year>2016</year><volume>2</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.86</pub-id><pub-id pub-id-type="pmid">27905473</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Schiffman M, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2(1):1&#8211;20.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2016.86</pub-id><pub-id pub-id-type="pmid">27905473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Human papillomaviruses; epithelial tropisms, and the development of neoplasia</article-title><source>Viruses</source><year>2015</year><volume>7</volume><issue>7</issue><fpage>3863</fpage><lpage>3890</lpage><pub-id pub-id-type="doi">10.3390/v7072802</pub-id><pub-id pub-id-type="pmid">26193301</pub-id><pub-id pub-id-type="pmcid">PMC4517131</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Egawa N, et al. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863&#8211;90.<pub-id pub-id-type="pmid">26193301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v7072802</pub-id><pub-id pub-id-type="pmcid">PMC4517131</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches</article-title><source>Infect Genet Evol</source><year>2017</year><volume>54</volume><fpage>402</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.08.002</pub-id><pub-id pub-id-type="pmid">28780192</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Negahdaripour M, et al. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches. Infect Genet Evol. 2017;54:402&#8211;16.<pub-id pub-id-type="pmid">28780192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2017.08.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delory</surname><given-names>T</given-names></name><etal/></person-group><article-title>Human papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand</article-title><source>J Infect</source><year>2017</year><volume>74</volume><issue>5</issue><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2017.02.007</pub-id><pub-id pub-id-type="pmid">28254419</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Delory T, et al. Human papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand. J Infect. 2017;74(5):501&#8211;11.<pub-id pub-id-type="pmid">28254419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2017.02.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Human papillomavirus and associated cancers: a review</article-title><source>Viruses</source><year>2024</year><volume>16</volume><issue>5</issue><fpage>680</fpage><pub-id pub-id-type="doi">10.3390/v16050680</pub-id><pub-id pub-id-type="pmid">38793561</pub-id><pub-id pub-id-type="pmcid">PMC11125882</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jensen JE, et al. Human papillomavirus and associated cancers: a review. Viruses. 2024;16(5):680.<pub-id pub-id-type="pmid">38793561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v16050680</pub-id><pub-id pub-id-type="pmcid">PMC11125882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name><name name-style="western"><surname>Day</surname><given-names>PM</given-names></name><name name-style="western"><surname>Kines</surname><given-names>RC</given-names></name></person-group><article-title>Current understanding of the mechanism of HPV infection</article-title><source>Gynecol Oncol</source><year>2010</year><volume>118</volume><issue>1</issue><fpage>S12</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2010.04.004</pub-id><pub-id pub-id-type="pmid">20494219</pub-id><pub-id pub-id-type="pmcid">PMC3493113</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(1):S12&#8211;7.<pub-id pub-id-type="pmid">20494219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2010.04.004</pub-id><pub-id pub-id-type="pmcid">PMC3493113</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehoux</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Abramo</surname><given-names>CM</given-names></name><name name-style="western"><surname>Archambault</surname><given-names>J</given-names></name></person-group><article-title>Molecular mechanisms of human papillomavirus-induced carcinogenesis</article-title><source>Public Health Genom</source><year>2009</year><volume>12</volume><issue>5&#8211;6</issue><fpage>268</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1159/000214918</pub-id><pub-id pub-id-type="pmcid">PMC4654617</pub-id><pub-id pub-id-type="pmid">19684440</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lehoux M, D&#8217;Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genom. 2009;12(5&#8211;6):268&#8211;80.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000214918</pub-id><pub-id pub-id-type="pmcid">PMC4654617</pub-id><pub-id pub-id-type="pmid">19684440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panatto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Human papillomavirus vaccine: State of the art and future perspectives</article-title><source>Adv Protein Chem Struct Biol</source><year>2015</year><volume>101</volume><fpage>231</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/bs.apcsb.2015.08.004</pub-id><pub-id pub-id-type="pmid">26572981</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Panatto D, et al. Human papillomavirus vaccine: State of the art and future perspectives. Adv Protein Chem Struct Biol. 2015;101:231&#8211;322.<pub-id pub-id-type="pmid">26572981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2015.08.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Murillo R and Ord&#243;&#241;ez-Reyes C, Human papillomavirus (HPV) vaccination: From clinical studies to immunization programs<italic toggle="yes">.</italic> International Journal of Gynecologic Cancer, 2019. <bold>29</bold>(8).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ijgc-2019-000582</pub-id><pub-id pub-id-type="pmid">31455660</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamolratanakul</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name></person-group><article-title>Human papillomavirus vaccine efficacy and effectiveness against cancer</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><issue>12</issue><fpage>1413</fpage><pub-id pub-id-type="doi">10.3390/vaccines9121413</pub-id><pub-id pub-id-type="pmid">34960159</pub-id><pub-id pub-id-type="pmcid">PMC8706722</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer. Vaccines. 2021;9(12):1413.<pub-id pub-id-type="pmid">34960159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9121413</pub-id><pub-id pub-id-type="pmcid">PMC8706722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">&#8220;WHO adds an HPV vaccine for single-dose use.&#8221; Access Date: Nov. 06, 2024. [Online]. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news/item/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use">https://www.who.int/news/item/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use</ext-link><italic toggle="yes">.</italic></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F-C</given-names></name><etal/></person-group><article-title>Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18&#8211;26 years in China: A randomised blinded clinical trial</article-title><source>Lancet Infect Dis</source><year>2023</year><volume>23</volume><issue>11</issue><fpage>1313</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00275-X</pub-id><pub-id pub-id-type="pmid">37475116</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhu F-C, et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18&#8211;26 years in China: A randomised blinded clinical trial. Lancet Infect Dis. 2023;23(11):1313&#8211;22.<pub-id pub-id-type="pmid">37475116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(23)00275-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Characterization of virus-like particles in GARDASIL&#174; by cryo transmission electron microscopy</article-title><source>Hum Vaccin Immunother</source><year>2014</year><volume>10</volume><issue>3</issue><fpage>734</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.4161/hv.27316</pub-id><pub-id pub-id-type="pmid">24299977</pub-id><pub-id pub-id-type="pmcid">PMC4130261</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhao Q, et al. Characterization of virus-like particles in GARDASIL&#174; by cryo transmission electron microscopy. Hum Vaccin Immunother. 2014;10(3):734&#8211;9.<pub-id pub-id-type="pmid">24299977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.27316</pub-id><pub-id pub-id-type="pmcid">PMC4130261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recommended adult immunization schedule, United States, 2020</article-title><source>Ann Intern Med</source><year>2020</year><volume>172</volume><issue>5</issue><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.7326/M20-0046</pub-id><pub-id pub-id-type="pmid">32016359</pub-id><pub-id pub-id-type="pmcid">PMC9555290</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Freedman M, et al. Recommended adult immunization schedule, United States, 2020. Ann Intern Med. 2020;172(5):337&#8211;47.<pub-id pub-id-type="pmid">32016359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-0046</pub-id><pub-id pub-id-type="pmcid">PMC9555290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">HPV CH, FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)<italic toggle="yes">.</italic> 2010.<pub-id pub-id-type="pmid">20508593</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP)</article-title><source>Morb Mortal Wkly Rep</source><year>2014</year><volume>63</volume><issue>5</issue><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">25167164</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Markowitz LE, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2014;63(5):1&#8211;30.<pub-id pub-id-type="pmid">25167164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joura</surname><given-names>EA</given-names></name><etal/></person-group><article-title>A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>8</issue><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1405044</pub-id><pub-id pub-id-type="pmid">25693011</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Joura EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711&#8211;23.<pub-id pub-id-type="pmid">25693011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1405044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>Y-L</given-names></name><etal/></person-group><article-title>Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial</article-title><source>JNCI J Nat Cancer Inst</source><year>2020</year><volume>112</volume><issue>2</issue><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1093/jnci/djz074</pub-id><pub-id pub-id-type="pmid">31086947</pub-id><pub-id pub-id-type="pmcid">PMC7019098</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Qiao Y-L, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. JNCI J Nat Cancer Inst. 2020;112(2):145&#8211;53.<pub-id pub-id-type="pmid">31086947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz074</pub-id><pub-id pub-id-type="pmcid">PMC7019098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y-M</given-names></name><etal/></person-group><article-title>Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs 3 doses in young women</article-title><source>Sci China Life Sci</source><year>2020</year><volume>63</volume><issue>4</issue><fpage>582</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1007/s11427-019-9547-7</pub-id><pub-id pub-id-type="pmid">31231780</pub-id><pub-id pub-id-type="pmcid">PMC7223315</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hu Y-M, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs 3 doses in young women. Sci China Life Sci. 2020;63(4):582&#8211;91.<pub-id pub-id-type="pmid">31231780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-019-9547-7</pub-id><pub-id pub-id-type="pmcid">PMC7223315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Recombinant Human Papillomavirus Bivalent (Types 16, V.P.p., Package Insert, Walvax Yuxi Zerun Biotechnology Co., Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.walvax.com/media/upload/product/Package%20Insert%20of%20HPV2.pdf">https://en.walvax.com/media/upload/product/Package%20Insert%20of%20HPV2.pdf</ext-link>, 2023. .</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Serum Institute of India PVT LTD., P.s.i.I., Cervavac, Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.seruminstitute.com/product_ind_cervavac.php">https://www.seruminstitute.com/product_ind_cervavac.php</ext-link>, 2023.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Cox, J.T. and J.M. Palefsky, <italic toggle="yes">Human papillomavirus vaccination.</italic> UpToDate. Waltham, MA. Accessed September, 2018. <bold>15</bold>.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Sanjose</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><issue>11</issue><fpage>1048</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70230-8</pub-id><pub-id pub-id-type="pmid">20952254</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">De Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048&#8211;56.<pub-id pub-id-type="pmid">20952254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(10)70230-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castle</surname><given-names>PE</given-names></name><name name-style="western"><surname>Maza</surname><given-names>M</given-names></name></person-group><article-title>Prophylactic HPV vaccination: past, present, and future</article-title><source>Epidemiol Infect</source><year>2016</year><volume>144</volume><issue>3</issue><fpage>449</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1017/S0950268815002198</pub-id><pub-id pub-id-type="pmid">26429676</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449&#8211;68.<pub-id pub-id-type="pmid">26429676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268815002198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>TC</given-names></name><name name-style="western"><surname>Casella</surname><given-names>CR</given-names></name></person-group><article-title>No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines</article-title><source>Curr Opin Immunol</source><year>2017</year><volume>47</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.06.009</pub-id><pub-id pub-id-type="pmid">28728074</pub-id><pub-id pub-id-type="pmcid">PMC5626597</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Mitchell TC, Casella CR. No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines. Curr Opin Immunol. 2017;47:17&#8211;25.<pub-id pub-id-type="pmid">28728074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2017.06.009</pub-id><pub-id pub-id-type="pmcid">PMC5626597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlecht</surname><given-names>NF</given-names></name><etal/></person-group><article-title>Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine</article-title><source>JAMA Netw Open</source><year>2019</year><volume>2</volume><issue>10</issue><fpage>e1914031</fpage><lpage>e1914031</lpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.14031</pub-id><pub-id pub-id-type="pmid">31651968</pub-id><pub-id pub-id-type="pmcid">PMC6822084</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Schlecht NF, et al. Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine. JAMA Netw Open. 2019;2(10):e1914031&#8211;e1914031.<pub-id pub-id-type="pmid">31651968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.14031</pub-id><pub-id pub-id-type="pmcid">PMC6822084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>DY</given-names></name><name name-style="western"><surname>Bracken</surname><given-names>K</given-names></name></person-group><article-title>Update on the new 9-valent vaccine for human papillomavirus prevention</article-title><source>Can Fam Physician</source><year>2016</year><volume>62</volume><issue>5</issue><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">27255620</pub-id><pub-id pub-id-type="pmcid">PMC4865336</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician. 2016;62(5):399&#8211;402.<pub-id pub-id-type="pmid">27255620</pub-id><pub-id pub-id-type="pmcid">PMC4865336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><etal/></person-group><article-title>A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>1</issue><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.11.029</pub-id><pub-id pub-id-type="pmid">33243631</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hu S, et al. A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China. Vaccine. 2021;39(1):35&#8211;44.<pub-id pub-id-type="pmid">33243631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.11.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9&#8211;14-year-old and 18&#8211;26-year-old Chinese females: a randomized, double-blind, non-inferiority clinical trial</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><issue>48</issue><fpage>7212</fpage><lpage>7219</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.10.041</pub-id><pub-id pub-id-type="pmid">39492306</pub-id><pub-id pub-id-type="pmcid">PMC10680975</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Li J, et al. Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9&#8211;14-year-old and 18&#8211;26-year-old Chinese females: a randomized, double-blind, non-inferiority clinical trial. Vaccine. 2023;41(48):7212&#8211;9.<pub-id pub-id-type="pmid">39492306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2023.10.041</pub-id><pub-id pub-id-type="pmcid">PMC10680975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>H</given-names></name><etal/></person-group><article-title>A phase-I, open label clinical trial to assess the safety &amp; tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt</article-title><source>Ltd in adults Vaccine: X</source><year>2023</year><volume>14</volume><fpage>100313</fpage><pub-id pub-id-type="pmid">37234594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvacx.2023.100313</pub-id><pub-id pub-id-type="pmcid">PMC10205786</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Sharma H, et al. A phase-I, open label clinical trial to assess the safety &amp; tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd in adults Vaccine: X. 2023;14: 100313.<pub-id pub-id-type="pmid">37234594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvacx.2023.100313</pub-id><pub-id pub-id-type="pmcid">PMC10205786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structural vaccinology considerations for in silico designing of a multi-epitope vaccine</article-title><source>Infect Genet Evol</source><year>2018</year><volume>58</volume><fpage>96</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.12.008</pub-id><pub-id pub-id-type="pmid">29253673</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Negahdaripour M, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. Infect Genet Evol. 2018;58:96&#8211;109.<pub-id pub-id-type="pmid">29253673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2017.12.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Moreira ED, et al. Safety profile of the 9-valent HPV vaccine a combined analysis of 7 phase III clinical trials<italic toggle="yes">.</italic> Pediatrics, 2016. 138(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2015-4387</pub-id><pub-id pub-id-type="pmid">27422279</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>A</given-names></name><etal/></person-group><article-title>Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines</article-title><source>Pediatrics</source><year>2015</year><volume>136</volume><issue>3</issue><fpage>e563</fpage><lpage>e572</lpage><pub-id pub-id-type="doi">10.1542/peds.2014-4199</pub-id><pub-id pub-id-type="pmid">26240207</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Schilling A, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136(3):e563&#8211;72.<pub-id pub-id-type="pmid">26240207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2014-4199</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Organization</surname><given-names>WH</given-names></name></person-group><source>One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer</source><year>2022</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><pub-id pub-id-type="pmcid">PMC9280593</pub-id><pub-id pub-id-type="pmid">35537734</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="book">Organization WH. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. Geneva: World Health Organization; 2022.<pub-id pub-id-type="pmcid">PMC9280593</pub-id><pub-id pub-id-type="pmid">35537734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">World Health Organization, Weekly epidemiological record, Human papillomavirus vaccines: WHO position paper (2022 update), Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://iris.who.int/bitstream/handle/10665/365350/WER9750-eng-fre.pdf?sequence=1">https://iris.who.int/bitstream/handle/10665/365350/WER9750-eng-fre.pdf?sequence=1</ext-link><italic toggle="yes">.</italic></mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baisley</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparing one dose of HPV vaccine in girls aged 9&#8211;14 years in Tanzania (DoRIS) with one dose in young women aged 15&#8211;20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials</article-title><source>Lancet Glob Health</source><year>2024</year><volume>12</volume><issue>3</issue><fpage>e491</fpage><lpage>e499</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(23)00586-7</pub-id><pub-id pub-id-type="pmid">38365419</pub-id><pub-id pub-id-type="pmcid">PMC10882205</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Baisley K, et al. Comparing one dose of HPV vaccine in girls aged 9&#8211;14 years in Tanzania (DoRIS) with one dose in young women aged 15&#8211;20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials. Lancet Glob Health. 2024;12(3):e491&#8211;9.<pub-id pub-id-type="pmid">38365419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(23)00586-7</pub-id><pub-id pub-id-type="pmcid">PMC10882205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety of human papillomavirus vaccines: an updated review</article-title><source>Drug Saf</source><year>2018</year><volume>41</volume><issue>4</issue><fpage>329</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1007/s40264-017-0625-z</pub-id><pub-id pub-id-type="pmid">29280070</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Phillips A, et al. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018;41(4):329&#8211;46.<pub-id pub-id-type="pmid">29280070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-017-0625-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gon&#231;alves</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review</article-title><source>Braz J Infect Dis</source><year>2014</year><volume>18</volume><fpage>651</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2014.02.005</pub-id><pub-id pub-id-type="pmid">24780368</pub-id><pub-id pub-id-type="pmcid">PMC9425215</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gon&#231;alves AK, et al. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014;18:651&#8211;9.<pub-id pub-id-type="pmid">24780368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bjid.2014.02.005</pub-id><pub-id pub-id-type="pmcid">PMC9425215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrosky</surname><given-names>E</given-names></name><etal/></person-group><article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2015</year><volume>64</volume><issue>11</issue><fpage>300</fpage><pub-id pub-id-type="pmid">25811679</pub-id><pub-id pub-id-type="pmcid">PMC4584883</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Petrosky E, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300.<pub-id pub-id-type="pmid">25811679</pub-id><pub-id pub-id-type="pmcid">PMC4584883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safaeian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial</article-title><source>Cancer Prev Res</source><year>2013</year><volume>6</volume><issue>11</issue><fpage>1242</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-13-0203</pub-id><pub-id pub-id-type="pmcid">PMC7605443</pub-id><pub-id pub-id-type="pmid">24189371</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Safaeian M, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res. 2013;6(11):1242&#8211;50.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-13-0203</pub-id><pub-id pub-id-type="pmcid">PMC7605443</pub-id><pub-id pub-id-type="pmid">24189371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreimer</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>7</issue><fpage>775</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00047-9</pub-id><pub-id pub-id-type="pmid">26071347</pub-id><pub-id pub-id-type="pmcid">PMC4498478</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kreimer AR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16(7):775&#8211;86.<pub-id pub-id-type="pmid">26071347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(15)00047-9</pub-id><pub-id pub-id-type="pmcid">PMC4498478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;nard</surname><given-names>&#201;</given-names></name><etal/></person-group><article-title>Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis</article-title><source>The Lancet Public Health</source><year>2023</year><volume>8</volume><issue>10</issue><fpage>e788</fpage><lpage>e799</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(23)00180-9</pub-id><pub-id pub-id-type="pmid">37777288</pub-id><pub-id pub-id-type="pmcid">PMC10557953</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">B&#233;nard &#201;, et al. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis. The Lancet Public Health. 2023;8(10):e788&#8211;99.<pub-id pub-id-type="pmid">37777288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(23)00180-9</pub-id><pub-id pub-id-type="pmcid">PMC10557953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>DR</given-names></name></person-group><article-title>Raising expectations for subunit vaccine</article-title><source>J Infect Dis</source><year>2015</year><volume>211</volume><issue>9</issue><fpage>1373</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu648</pub-id><pub-id pub-id-type="pmid">25420478</pub-id><pub-id pub-id-type="pmcid">PMC4400525</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373&#8211;5.<pub-id pub-id-type="pmid">25420478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiu648</pub-id><pub-id pub-id-type="pmcid">PMC4400525</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariani</surname><given-names>L</given-names></name><name name-style="western"><surname>Venuti</surname><given-names>A</given-names></name></person-group><article-title>HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future</article-title><source>J Transl Med</source><year>2010</year><volume>8</volume><issue>1</issue><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-8-105</pub-id><pub-id pub-id-type="pmid">20979636</pub-id><pub-id pub-id-type="pmcid">PMC2988719</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010;8(1):105.<pub-id pub-id-type="pmid">20979636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1479-5876-8-105</pub-id><pub-id pub-id-type="pmcid">PMC2988719</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Roden</surname><given-names>RB</given-names></name></person-group><article-title>Virus-like particles for the prevention of human papillomavirus-associated malignancies</article-title><source>Expert Rev Vaccines</source><year>2013</year><volume>12</volume><issue>2</issue><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1586/erv.12.151</pub-id><pub-id pub-id-type="pmid">23414405</pub-id><pub-id pub-id-type="pmcid">PMC3835148</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines. 2013;12(2):129&#8211;41.<pub-id pub-id-type="pmid">23414405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.12.151</pub-id><pub-id pub-id-type="pmcid">PMC3835148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Gallego LS, Dominguez A, and Parmar M, <italic toggle="yes">Human Papilloma Virus (HPV) Vaccine.</italic> StatPearls [Internet], 2020.</mixed-citation></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>LA</given-names></name><name name-style="western"><surname>Trimble</surname><given-names>C</given-names></name></person-group><article-title>Human papillomavirus vaccines&#8211;immune responses</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>F83</fpage><lpage>F87</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.106</pub-id><pub-id pub-id-type="pmid">23199968</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines&#8211;immune responses. Vaccine. 2012;30:F83&#8211;7.<pub-id pub-id-type="pmid">23199968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.04.106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kjaer</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries</article-title><source>EClinicalMedicine</source><year>2020</year><volume>23</volume><fpage>100401</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100401</pub-id><pub-id pub-id-type="pmid">32637895</pub-id><pub-id pub-id-type="pmcid">PMC7329692</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Kjaer SK, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020;23:100401.<pub-id pub-id-type="pmid">32637895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2020.100401</pub-id><pub-id pub-id-type="pmcid">PMC7329692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurosawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term effects of human papillomavirus vaccination in clinical trials and real-world data: a systematic review</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>256</fpage><pub-id pub-id-type="doi">10.3390/vaccines10020256</pub-id><pub-id pub-id-type="pmid">35214713</pub-id><pub-id pub-id-type="pmcid">PMC8877934</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Kurosawa M, et al. Long-term effects of human papillomavirus vaccination in clinical trials and real-world data: a systematic review. Vaccines. 2022;10(2):256.<pub-id pub-id-type="pmid">35214713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10020256</pub-id><pub-id pub-id-type="pmcid">PMC8877934</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation</article-title><source>JNCI J Nat Cancer Inst</source><year>2024</year><volume>116</volume><issue>6</issue><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1093/jnci/djad263</pub-id><pub-id pub-id-type="pmid">38247547</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Palmer TJ, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. JNCI J Nat Cancer Inst. 2024;116(6):857&#8211;65.<pub-id pub-id-type="pmid">38247547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djad263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malag&#243;n</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2012</year><volume>12</volume><issue>10</issue><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(12)70187-1</pub-id><pub-id pub-id-type="pmid">22920953</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Malag&#243;n T, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781&#8211;9.<pub-id pub-id-type="pmid">22920953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(12)70187-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freire-Salinas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain</article-title><source>Front Cell Infect Microbiol</source><year>2021</year><volume>11</volume><fpage>633162</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.633162</pub-id><pub-id pub-id-type="pmid">34631594</pub-id><pub-id pub-id-type="pmcid">PMC8493034</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Freire-Salinas J, et al. Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain. Front Cell Infect Microbiol. 2021;11: 633162.<pub-id pub-id-type="pmid">34631594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2021.633162</pub-id><pub-id pub-id-type="pmcid">PMC8493034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F</given-names></name></person-group><article-title>Advances and challenges in enveloped virus-like particle (VLP)-based vaccines</article-title><source>J Immunol Sci</source><year>2018</year><volume>2</volume><issue>2</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.29245/2578-3009/2018/2.1118</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci. 2018;2(2):36.</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T-C</given-names></name></person-group><article-title>How will HPV vaccines affect cervical cancer?</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><issue>10</issue><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/nrc1973</pub-id><pub-id pub-id-type="pmid">16990853</pub-id><pub-id pub-id-type="pmcid">PMC3181152</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Roden R, Wu T-C. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006;6(10):753&#8211;63.<pub-id pub-id-type="pmid">16990853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1973</pub-id><pub-id pub-id-type="pmcid">PMC3181152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>L</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name></person-group><article-title>Gardasil-9: a global survey of projected efficacy</article-title><source>Antiviral Res</source><year>2016</year><volume>130</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.03.016</pub-id><pub-id pub-id-type="pmid">27040313</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. Antiviral Res. 2016;130:101&#8211;9.<pub-id pub-id-type="pmid">27040313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2016.03.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruni</surname><given-names>L</given-names></name><etal/></person-group><article-title>Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis</article-title><source>Lancet Glob Health</source><year>2016</year><volume>4</volume><issue>7</issue><fpage>e453</fpage><lpage>e463</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(16)30099-7</pub-id><pub-id pub-id-type="pmid">27340003</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Bruni L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453&#8211;63.<pub-id pub-id-type="pmid">27340003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(16)30099-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peabody</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature</article-title><source>Papillomavirus Research</source><year>2017</year><volume>3</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.pvr.2017.03.004</pub-id><pub-id pub-id-type="pmid">28720444</pub-id><pub-id pub-id-type="pmcid">PMC5604873</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Peabody J, et al. Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Research. 2017;3:116&#8211;20.<pub-id pub-id-type="pmid">28720444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pvr.2017.03.004</pub-id><pub-id pub-id-type="pmcid">PMC5604873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beddoe</surname><given-names>AM</given-names></name></person-group><article-title>Elimination of cervical cancer challenges for developing countries</article-title><source>Ecancermedicalscience</source><year>2019</year><volume>13</volume><fpage>975</fpage><pub-id pub-id-type="doi">10.3332/ecancer.2019.975</pub-id><pub-id pub-id-type="pmid">31921346</pub-id><pub-id pub-id-type="pmcid">PMC6946419</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Beddoe AM. Elimination of cervical cancer challenges for developing countries. Ecancermedicalscience. 2019;13:975.<pub-id pub-id-type="pmid">31921346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3332/ecancer.2019.975</pub-id><pub-id pub-id-type="pmcid">PMC6946419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>E</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>R</given-names></name></person-group><article-title>Prevention of cervical cancer in sub-saharan africa: the advantages and challenges of HPV vaccination</article-title><source>Vaccination</source><year>2018</year><volume>6</volume><fpage>61</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines6030061</pub-id><pub-id pub-id-type="pmcid">PMC6161067</pub-id><pub-id pub-id-type="pmid">30205561</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Black E, Richmond R. Prevention of cervical cancer in sub-saharan africa: the advantages and challenges of HPV vaccination. Vaccination. 2018;6:61.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines6030061</pub-id><pub-id pub-id-type="pmcid">PMC6161067</pub-id><pub-id pub-id-type="pmid">30205561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>B</given-names></name><etal/></person-group><article-title>RG1-VLP and Other L2-based, broad-spectrum HPV vaccine candidates</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><issue>5</issue><fpage>1044</fpage><pub-id pub-id-type="doi">10.3390/jcm10051044</pub-id><pub-id pub-id-type="pmid">33802456</pub-id><pub-id pub-id-type="pmcid">PMC7959455</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Huber B, et al. RG1-VLP and Other L2-based, broad-spectrum HPV vaccine candidates. J Clin Med. 2021;10(5):1044.<pub-id pub-id-type="pmid">33802456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10051044</pub-id><pub-id pub-id-type="pmcid">PMC7959455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagheri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches</article-title><source>Infect Genet Evol</source><year>2021</year><volume>95</volume><fpage>105084</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105084</pub-id><pub-id pub-id-type="pmid">34547435</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Bagheri A, et al. Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches. Infect Genet Evol. 2021;95: 105084.<pub-id pub-id-type="pmid">34547435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2021.105084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: an in silico approach</article-title><source>Biologicals</source><year>2015</year><volume>43</volume><issue>5</issue><fpage>344</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2015.07.002</pub-id><pub-id pub-id-type="pmid">26212000</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kumar A, et al. Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: an in silico approach. Biologicals. 2015;43(5):344&#8211;8.<pub-id pub-id-type="pmid">26212000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biologicals.2015.07.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badillo-Godinez</surname><given-names>O</given-names></name><etal/></person-group><article-title>Induction of therapeutic protection in an HPV16-associated mouse tumor model through targeting the human papillomavirus-16 E5 protein to dendritic cells</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>593161</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.593161</pub-id><pub-id pub-id-type="pmid">33717073</pub-id><pub-id pub-id-type="pmcid">PMC7947241</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Badillo-Godinez O, et al. Induction of therapeutic protection in an HPV16-associated mouse tumor model through targeting the human papillomavirus-16 E5 protein to dendritic cells. Front Immunol. 2021;12: 593161.<pub-id pub-id-type="pmid">33717073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.593161</pub-id><pub-id pub-id-type="pmcid">PMC7947241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namvar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Development of HPV 16, 18, 31, 45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools</article-title><source>Biotech Lett</source><year>2020</year><volume>42</volume><fpage>403</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02792-6</pub-id><pub-id pub-id-type="pmcid">PMC7087594</pub-id><pub-id pub-id-type="pmid">31915962</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Namvar A, et al. Development of HPV 16, 18, 31, 45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools. Biotech Lett. 2020;42:403&#8211;18.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10529-020-02792-6</pub-id><pub-id pub-id-type="pmcid">PMC7087594</pub-id><pub-id pub-id-type="pmid">31915962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hildesheim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection</article-title><source>JAMA</source><year>2007</year><volume>298</volume><issue>7</issue><fpage>743</fpage><pub-id pub-id-type="doi">10.1001/jama.298.7.743</pub-id><pub-id pub-id-type="pmid">17699008</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Hildesheim A, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA. 2007;298(7):743.<pub-id pub-id-type="pmid">17699008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.298.7.743</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name><name name-style="western"><surname>Castellsagu&#233;</surname><given-names>X</given-names></name><name name-style="western"><surname>Garland</surname><given-names>SM</given-names></name></person-group><article-title>A review of clinical trials of human papillomavirus prophylactic vaccines</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>F123</fpage><lpage>F138</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.108</pub-id><pub-id pub-id-type="pmid">23199956</pub-id><pub-id pub-id-type="pmcid">PMC4636904</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Schiller JT, Castellsagu&#233; X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123&#8211;38.<pub-id pub-id-type="pmid">23199956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.04.108</pub-id><pub-id pub-id-type="pmcid">PMC4636904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fatemi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Seifi</surname><given-names>N</given-names></name><name name-style="western"><surname>Rasekh</surname><given-names>S</given-names></name><name name-style="western"><surname>Amiri</surname><given-names>S</given-names></name><name name-style="western"><surname>Moezzi</surname><given-names>SMI</given-names></name><name name-style="western"><surname>Bagheri</surname><given-names>A</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>S</given-names></name><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name></person-group><article-title>Immunotherapeutic approaches for HPV-caused cervical cancer</article-title><source>Immunotherapeutics</source><year>2022</year><publisher-name>Elsevier</publisher-name><fpage>51</fpage><lpage>90</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2021.11.002</pub-id><pub-id pub-id-type="pmid">35305725</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="book">Fatemi SA, Seifi N, Rasekh S, Amiri S, Moezzi SMI, Bagheri A, Fathi S, Negahdaripour M. Immunotherapeutic approaches for HPV-caused cervical cancer. In: Immunotherapeutics. Elsevier; 2022. p. 51&#8211;90. 10.1016/bs.apcsb.2021.11.002.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2021.11.002</pub-id><pub-id pub-id-type="pmid">35305725</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>B</given-names></name><etal/></person-group><article-title>Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV)</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>1</issue><fpage>e0169533</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0169533</pub-id><pub-id pub-id-type="pmid">28056100</pub-id><pub-id pub-id-type="pmcid">PMC5215943</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Huber B, et al. Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV). PLoS ONE. 2017;12(1): e0169533.<pub-id pub-id-type="pmid">28056100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0169533</pub-id><pub-id pub-id-type="pmcid">PMC5215943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellenbacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R</given-names></name><name name-style="western"><surname>Kirnbauer</surname><given-names>R</given-names></name></person-group><article-title>Chimeric L1&#8211;L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines</article-title><source>J Virol</source><year>2009</year><volume>83</volume><issue>19</issue><fpage>10085</fpage><lpage>10095</lpage><pub-id pub-id-type="doi">10.1128/JVI.01088-09</pub-id><pub-id pub-id-type="pmid">19640991</pub-id><pub-id pub-id-type="pmcid">PMC2748020</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1&#8211;L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol. 2009;83(19):10085&#8211;95.<pub-id pub-id-type="pmid">19640991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01088-09</pub-id><pub-id pub-id-type="pmcid">PMC2748020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques</article-title><source>Papillomavirus Res</source><year>2020</year><volume>10</volume><fpage>100209</fpage><pub-id pub-id-type="doi">10.1016/j.pvr.2020.100209</pub-id><pub-id pub-id-type="pmid">33197649</pub-id><pub-id pub-id-type="pmcid">PMC7704424</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Wang Y, et al. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques. Papillomavirus Res. 2020;10: 100209.<pub-id pub-id-type="pmid">33197649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pvr.2020.100209</pub-id><pub-id pub-id-type="pmcid">PMC7704424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>PL</given-names></name><name name-style="western"><surname>Roden</surname><given-names>RB</given-names></name></person-group><article-title>Opportunities to improve immune-based prevention of HPV-associated cancers</article-title><source>Papillomavirus Res</source><year>2019</year><volume>7</volume><fpage>150</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.pvr.2019.04.010</pub-id><pub-id pub-id-type="pmid">30980968</pub-id><pub-id pub-id-type="pmcid">PMC6468155</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Stern PL, Roden RB. Opportunities to improve immune-based prevention of HPV-associated cancers. Papillomavirus Res. 2019;7:150&#8211;3.<pub-id pub-id-type="pmid">30980968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pvr.2019.04.010</pub-id><pub-id pub-id-type="pmcid">PMC6468155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>RB</given-names></name><name name-style="western"><surname>Stern</surname><given-names>PL</given-names></name></person-group><article-title>Opportunities and challenges for human papillomavirus vaccination in cancer</article-title><source>Nat Rev Cancer</source><year>2018</year><volume>18</volume><issue>4</issue><fpage>240</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nrc.2018.13</pub-id><pub-id pub-id-type="pmid">29497146</pub-id><pub-id pub-id-type="pmcid">PMC6454884</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Roden RB, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240&#8211;54.<pub-id pub-id-type="pmid">29497146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2018.13</pub-id><pub-id pub-id-type="pmcid">PMC6454884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05262010">NCT05262010</ext-link>, ClinicalTrials.gov. Access date: Feb. 2023.</mixed-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02710851">NCT02710851</ext-link>, ClinicalTrials.gov. Access date: Feb. 2023.</mixed-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04425291">NCT04425291</ext-link>, ClinicalTrials.gov. Access date: Feb. 2023.</mixed-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05056402">NCT05056402</ext-link>, ClinicalTrials.gov. Access date: Feb. 2023.</mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Assessment of the safety, t., and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers: A double-blinded, randomized, adjuvant vehicle-controlled trial, Clinical Research Iinformation Service (CRIS), Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cris.nih.go.kr/cris/search/detailSearch.do?seq=2624&amp;search_page=L&amp;search_lang=E&amp;lang=E&amp;latest=Y#step7">https://cris.nih.go.kr/cris/search/detailSearch.do?seq=2624&amp;search_page=L&amp;search_lang=E&amp;lang=E&amp;latest=Y#step7</ext-link>.</mixed-citation></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model</article-title><source>Acta Biochim Biophys Sin</source><year>2009</year><volume>41</volume><issue>2</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmn016</pub-id><pub-id pub-id-type="pmid">19204831</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Li W, et al. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Acta Biochim Biophys Sin. 2009;41(2):137&#8211;45.<pub-id pub-id-type="pmid">19204831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/abbs/gmn016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#228;dlich</surname><given-names>L</given-names></name><etal/></person-group><article-title>Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity</article-title><source>J Virol</source><year>2009</year><volume>83</volume><issue>15</issue><fpage>7690</fpage><lpage>7705</lpage><pub-id pub-id-type="doi">10.1128/JVI.02588-08</pub-id><pub-id pub-id-type="pmid">19457985</pub-id><pub-id pub-id-type="pmcid">PMC2708645</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Sch&#228;dlich L, et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol. 2009;83(15):7690&#8211;705.<pub-id pub-id-type="pmid">19457985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02588-08</pub-id><pub-id pub-id-type="pmcid">PMC2708645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E coli</article-title><source>Protein Exp Purif</source><year>2020</year><volume>175</volume><fpage>105690</fpage><pub-id pub-id-type="doi">10.1016/j.pep.2020.105690</pub-id><pub-id pub-id-type="pmid">32681956</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Roos N, et al. Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E coli. Protein Exp Purif. 2020;175:105690.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pep.2020.105690</pub-id><pub-id pub-id-type="pmid">32681956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassett</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Development of a highly thermostable, adjuvanted human papillomavirus vaccine</article-title><source>Eur J Pharm Biopharm</source><year>2015</year><volume>94</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.05.009</pub-id><pub-id pub-id-type="pmid">25998700</pub-id><pub-id pub-id-type="pmcid">PMC4524352</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Hassett KJ, et al. Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm. 2015;94:220&#8211;8.<pub-id pub-id-type="pmid">25998700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2015.05.009</pub-id><pub-id pub-id-type="pmcid">PMC4524352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Roden</surname><given-names>RB</given-names></name></person-group><article-title>L2, the minor capsid protein of papillomavirus</article-title><source>Virology</source><year>2013</year><volume>445</volume><issue>1&#8211;2</issue><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.04.017</pub-id><pub-id pub-id-type="pmid">23689062</pub-id><pub-id pub-id-type="pmcid">PMC3770800</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology. 2013;445(1&#8211;2):175&#8211;86.<pub-id pub-id-type="pmid">23689062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2013.04.017</pub-id><pub-id pub-id-type="pmcid">PMC3770800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyler</surname><given-names>M</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name><name name-style="western"><surname>Chackerian</surname><given-names>B</given-names></name></person-group><article-title>Second-generation prophylactic HPV vaccines: successes and challenges</article-title><source>Expert Rev Vaccines</source><year>2014</year><volume>13</volume><issue>2</issue><fpage>247</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.865523</pub-id><pub-id pub-id-type="pmid">24350614</pub-id><pub-id pub-id-type="pmcid">PMC4410880</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines. 2014;13(2):247&#8211;55.<pub-id pub-id-type="pmid">24350614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2014.865523</pub-id><pub-id pub-id-type="pmcid">PMC4410880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambhira</surname><given-names>R</given-names></name><etal/></person-group><article-title>A protective and broadly cross-neutralizing epitope of human papillomavirus L2</article-title><source>J Virol</source><year>2007</year><volume>81</volume><issue>24</issue><fpage>13927</fpage><lpage>13931</lpage><pub-id pub-id-type="doi">10.1128/JVI.00936-07</pub-id><pub-id pub-id-type="pmid">17928339</pub-id><pub-id pub-id-type="pmcid">PMC2168823</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Gambhira R, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol. 2007;81(24):13927&#8211;31.<pub-id pub-id-type="pmid">17928339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00936-07</pub-id><pub-id pub-id-type="pmcid">PMC2168823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slupetzky</surname><given-names>K</given-names></name><etal/></person-group><article-title>A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>11</issue><fpage>2001</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.11.049</pub-id><pub-id pub-id-type="pmid">17239496</pub-id><pub-id pub-id-type="pmcid">PMC3935451</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Slupetzky K, et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine. 2007;25(11):2001&#8211;10.<pub-id pub-id-type="pmid">17239496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.11.049</pub-id><pub-id pub-id-type="pmcid">PMC3935451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawana</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><issue>11&#8211;12</issue><fpage>1496</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00367-4</pub-id><pub-id pub-id-type="pmid">11163673</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Kawana K, et al. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine. 2001;19(11&#8211;12):1496&#8211;502.<pub-id pub-id-type="pmid">11163673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(00)00367-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawana</surname><given-names>K</given-names></name><etal/></person-group><article-title>Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6</article-title><source>J Virol</source><year>1999</year><volume>73</volume><issue>7</issue><fpage>6188</fpage><lpage>6190</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.7.6188-6190.1999</pub-id><pub-id pub-id-type="pmid">10364381</pub-id><pub-id pub-id-type="pmcid">PMC112690</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Kawana K, et al. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol. 1999;73(7):6188&#8211;90.<pub-id pub-id-type="pmid">10364381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.73.7.6188-6190.1999</pub-id><pub-id pub-id-type="pmcid">PMC112690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Immunoprevention of human papillomavirus-associated malignancies</article-title><source>Cancer Prev Res</source><year>2015</year><volume>8</volume><issue>2</issue><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-14-0311</pub-id><pub-id pub-id-type="pmcid">PMC4315720</pub-id><pub-id pub-id-type="pmid">25488410</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Wang JW, et al. Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res. 2015;8(2):95&#8211;104.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-14-0311</pub-id><pub-id pub-id-type="pmcid">PMC4315720</pub-id><pub-id pub-id-type="pmid">25488410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pouyanfard</surname><given-names>S</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></name></person-group><article-title>Human papillomavirus first and second generation vaccines&#8211;current status and future directions</article-title><source>Biol Chem</source><year>2017</year><volume>398</volume><issue>8</issue><fpage>871</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1515/hsz-2017-0105</pub-id><pub-id pub-id-type="pmid">28328521</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Pouyanfard S, M&#252;ller M. Human papillomavirus first and second generation vaccines&#8211;current status and future directions. Biol Chem. 2017;398(8):871&#8211;89.<pub-id pub-id-type="pmid">28328521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/hsz-2017-0105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticals</article-title><source>Expert Opin Biol Ther</source><year>2019</year><volume>19</volume><issue>12</issue><fpage>1275</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1080/14712598.2019.1652592</pub-id><pub-id pub-id-type="pmid">31382850</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Negahdaripour M, et al. Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticals. Expert Opin Biol Ther. 2019;19(12):1275&#8211;87.<pub-id pub-id-type="pmid">31382850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14712598.2019.1652592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croft</surname><given-names>NP</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>AW</given-names></name></person-group><article-title>Peptidomimetics: modifying peptides in the pursuit of better vaccines</article-title><source>Expert Rev Vaccines</source><year>2011</year><volume>10</volume><issue>2</issue><fpage>211</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1586/erv.10.161</pub-id><pub-id pub-id-type="pmid">21332270</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Croft NP, Purcell AW. Peptidomimetics: modifying peptides in the pursuit of better vaccines. Expert Rev Vaccines. 2011;10(2):211&#8211;26.<pub-id pub-id-type="pmid">21332270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.10.161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellenbacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Roden</surname><given-names>RB</given-names></name><name name-style="western"><surname>Kirnbauer</surname><given-names>R</given-names></name></person-group><article-title>Developments in L2-based human papillomavirus (HPV) vaccines</article-title><source>Virus Res</source><year>2017</year><volume>231</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.020</pub-id><pub-id pub-id-type="pmid">27889616</pub-id><pub-id pub-id-type="pmcid">PMC5549463</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Schellenbacher C, Roden RB, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017;231:166&#8211;75.<pub-id pub-id-type="pmid">27889616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2016.11.020</pub-id><pub-id pub-id-type="pmcid">PMC5549463</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Progress and prospects for L2-based human papillomavirus vaccines</article-title><source>Expert Rev Vaccines</source><year>2016</year><volume>15</volume><issue>7</issue><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1157479</pub-id><pub-id pub-id-type="pmid">26901354</pub-id><pub-id pub-id-type="pmcid">PMC4911254</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Jiang RT, et al. Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines. 2016;15(7):853&#8211;62.<pub-id pub-id-type="pmid">26901354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2016.1157479</pub-id><pub-id pub-id-type="pmcid">PMC4911254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellenbacher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses</article-title><source>J Investig Dermatol</source><year>2013</year><volume>133</volume><issue>12</issue><fpage>2706</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.253</pub-id><pub-id pub-id-type="pmid">23752042</pub-id><pub-id pub-id-type="pmcid">PMC3826974</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Schellenbacher C, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Investig Dermatol. 2013;133(12):2706&#8211;13.<pub-id pub-id-type="pmid">23752042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2013.253</pub-id><pub-id pub-id-type="pmcid">PMC3826974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellenbacher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>27</issue><fpage>3529</fpage><lpage>3534</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.011</pub-id><pub-id pub-id-type="pmid">31147274</pub-id><pub-id pub-id-type="pmcid">PMC6832690</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Schellenbacher C, et al. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine. 2019;37(27):3529&#8211;34.<pub-id pub-id-type="pmid">31147274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.05.011</pub-id><pub-id pub-id-type="pmcid">PMC6832690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice</article-title><source>Hum Vaccin Immunother</source><year>2018</year><volume>14</volume><issue>8</issue><fpage>2025</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1464355</pub-id><pub-id pub-id-type="pmid">29683766</pub-id><pub-id pub-id-type="pmcid">PMC6149973</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Chen X, et al. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Hum Vaccin Immunother. 2018;14(8):2025&#8211;33.<pub-id pub-id-type="pmid">29683766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2018.1464355</pub-id><pub-id pub-id-type="pmcid">PMC6149973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGrath</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of human papillomavirus chimaeric L1/L2 candidate vaccines</article-title><source>Adv Virol</source><year>2013</year><volume>158</volume><issue>10</issue><fpage>2079</fpage><lpage>2088</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-013-1713-8</pub-id><pub-id pub-id-type="pmid">23636405</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">McGrath M, et al. Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Adv Virol. 2013;158(10):2079&#8211;88.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-013-1713-8</pub-id><pub-id pub-id-type="pmid">23636405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>38</issue><fpage>63333</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.19327</pub-id><pub-id pub-id-type="pmid">28968993</pub-id><pub-id pub-id-type="pmcid">PMC5609925</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Chen X, et al. Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types. Oncotarget. 2017;8(38):63333.<pub-id pub-id-type="pmid">28968993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.19327</pub-id><pub-id pub-id-type="pmcid">PMC5609925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zacharia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>2</issue><fpage>292</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.11.066</pub-id><pub-id pub-id-type="pmid">33309485</pub-id><pub-id pub-id-type="pmcid">PMC7779753</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Zacharia A, et al. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists. Vaccine. 2021;39(2):292&#8211;302.<pub-id pub-id-type="pmid">33309485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.11.066</pub-id><pub-id pub-id-type="pmcid">PMC7779753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchooli</surname><given-names>A</given-names></name><etal/></person-group><article-title>VLP production from recombinant L1/L2 HPV-16 protein expressed in pichia pastoris</article-title><source>Protein Pept Lett</source><year>2018</year><volume>25</volume><issue>8</issue><fpage>783</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.2174/0929866525666180809124633</pub-id><pub-id pub-id-type="pmid">30091403</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Alireza S, et al. VLP production from recombinant L1/L2 HPV-16 protein expressed in pichia pastoris. Protein Pept Lett. 2018;25(8):783&#8211;90.<pub-id pub-id-type="pmid">30091403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929866525666180809124633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boxus</surname><given-names>M</given-names></name><etal/></person-group><article-title>Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles</article-title><source>J Virol</source><year>2016</year><volume>90</volume><issue>14</issue><fpage>6314</fpage><lpage>6325</lpage><pub-id pub-id-type="doi">10.1128/JVI.00449-16</pub-id><pub-id pub-id-type="pmid">27147749</pub-id><pub-id pub-id-type="pmcid">PMC4936133</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Boxus M, et al. Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles. J Virol. 2016;90(14):6314&#8211;25.<pub-id pub-id-type="pmid">27147749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00449-16</pub-id><pub-id pub-id-type="pmcid">PMC4936133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>B</given-names></name><etal/></person-group><article-title>A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>3</issue><fpage>e0120152</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0120152</pub-id><pub-id pub-id-type="pmid">25790098</pub-id><pub-id pub-id-type="pmcid">PMC4366228</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Huber B, et al. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS ONE. 2015;10(3): e0120152.<pub-id pub-id-type="pmid">25790098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0120152</pub-id><pub-id pub-id-type="pmcid">PMC4366228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabeda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Substitution of human papillomavirus type 16 L2 neutralizing epitopes into L1 surface loops: the effect on virus-like particle assembly and immunogenicity</article-title><source>Front Plant Sci</source><year>2019</year><volume>10</volume><fpage>779</fpage><pub-id pub-id-type="doi">10.3389/fpls.2019.00779</pub-id><pub-id pub-id-type="pmid">31281327</pub-id><pub-id pub-id-type="pmcid">PMC6597877</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Chabeda A, et al. Substitution of human papillomavirus type 16 L2 neutralizing epitopes into L1 surface loops: the effect on virus-like particle assembly and immunogenicity. Front Plant Sci. 2019;10:779.<pub-id pub-id-type="pmid">31281327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpls.2019.00779</pub-id><pub-id pub-id-type="pmcid">PMC6597877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name><etal/></person-group><article-title>VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e49751</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0049751</pub-id><pub-id pub-id-type="pmid">23185426</pub-id><pub-id pub-id-type="pmcid">PMC3501453</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Tumban E, et al. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS ONE. 2012;7(11): e49751.<pub-id pub-id-type="pmid">23185426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0049751</pub-id><pub-id pub-id-type="pmcid">PMC3501453</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>L</given-names></name><etal/></person-group><article-title>A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9</article-title><source>Antiviral Res</source><year>2017</year><volume>147</volume><fpage>116</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.09.012</pub-id><pub-id pub-id-type="pmid">28939477</pub-id><pub-id pub-id-type="pmcid">PMC5675787</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Zhai L, et al. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Res. 2017;147:116&#8211;23.<pub-id pub-id-type="pmid">28939477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2017.09.012</pub-id><pub-id pub-id-type="pmcid">PMC5675787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name><etal/></person-group><article-title>Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>29</issue><fpage>3346</fpage><lpage>3353</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.016</pub-id><pub-id pub-id-type="pmid">26003490</pub-id><pub-id pub-id-type="pmcid">PMC4468037</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Tumban E, et al. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine. 2015;33(29):3346&#8211;53.<pub-id pub-id-type="pmid">26003490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.05.016</pub-id><pub-id pub-id-type="pmcid">PMC4468037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyler</surname><given-names>M</given-names></name><etal/></person-group><article-title>The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine</article-title><source>Biotechnol Bioeng</source><year>2014</year><volume>111</volume><issue>12</issue><fpage>2398</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1002/bit.25311</pub-id><pub-id pub-id-type="pmid">24917327</pub-id><pub-id pub-id-type="pmcid">PMC4410690</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Tyler M, et al. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng. 2014;111(12):2398&#8211;406.<pub-id pub-id-type="pmid">24917327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bit.25311</pub-id><pub-id pub-id-type="pmcid">PMC4410690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head &amp; neck cancers and cervical cancer</article-title><source>Antiviral Res</source><year>2019</year><volume>166</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.03.012</pub-id><pub-id pub-id-type="pmid">30926288</pub-id><pub-id pub-id-type="pmcid">PMC6538018</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Zhai L, et al. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head &amp; neck cancers and cervical cancer. Antiviral Res. 2019;166:56&#8211;65.<pub-id pub-id-type="pmid">30926288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2019.03.012</pub-id><pub-id pub-id-type="pmcid">PMC6538018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mixed bacteriophage ms2-l2 vlps elicit long-lasting protective antibodies against hpv pseudovirus 51</article-title><source>Viruses</source><year>2021</year><volume>13</volume><issue>6</issue><fpage>1113</fpage><pub-id pub-id-type="doi">10.3390/v13061113</pub-id><pub-id pub-id-type="pmid">34200586</pub-id><pub-id pub-id-type="pmcid">PMC8227171</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Yadav R, et al. Mixed bacteriophage ms2-l2 vlps elicit long-lasting protective antibodies against hpv pseudovirus 51. Viruses. 2021;13(6):1113.<pub-id pub-id-type="pmid">34200586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13061113</pub-id><pub-id pub-id-type="pmcid">PMC8227171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>34</issue><fpage>4267</fpage><lpage>4274</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.054</pub-id><pub-id pub-id-type="pmid">24962748</pub-id><pub-id pub-id-type="pmcid">PMC4114576</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Tyler M, et al. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine. 2014;32(34):4267&#8211;74.<pub-id pub-id-type="pmid">24962748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.06.054</pub-id><pub-id pub-id-type="pmcid">PMC4114576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Development of AAVLP (HPV16/31L2) particles as broadly protective HPV vaccine candidate</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>e39741</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0039741</pub-id><pub-id pub-id-type="pmid">22761884</pub-id><pub-id pub-id-type="pmcid">PMC3384601</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Nieto K, et al. Development of AAVLP (HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS ONE. 2012;7(6): e39741.<pub-id pub-id-type="pmid">22761884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0039741</pub-id><pub-id pub-id-type="pmcid">PMC3384601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W-H</given-names></name><etal/></person-group><article-title>Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach</article-title><source>Virol J</source><year>2015</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s12985-015-0364-7</pub-id><pub-id pub-id-type="pmid">26362430</pub-id><pub-id pub-id-type="pmcid">PMC4566294</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Wu W-H, et al. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J. 2015;12(1):1&#8211;11.<pub-id pub-id-type="pmid">26362430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-015-0364-7</pub-id><pub-id pub-id-type="pmcid">PMC4566294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vujadinovic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><issue>30</issue><fpage>4462</fpage><lpage>4470</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.024</pub-id><pub-id pub-id-type="pmid">29914845</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Vujadinovic M, et al. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. Vaccine. 2018;36(30):4462&#8211;70.<pub-id pub-id-type="pmid">29914845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.06.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diamos</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>1</issue><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.021</pub-id><pub-id pub-id-type="pmid">30459071</pub-id><pub-id pub-id-type="pmcid">PMC6291209</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Diamos AG, et al. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. Vaccine. 2019;37(1):137&#8211;44.<pub-id pub-id-type="pmid">30459071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.11.021</pub-id><pub-id pub-id-type="pmcid">PMC6291209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>H</given-names></name><etal/></person-group><article-title>Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-L2 vaccine</article-title><source>Cancer Prev Res</source><year>2015</year><volume>8</volume><issue>10</issue><fpage>932</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-15-0164</pub-id><pub-id pub-id-type="pmid">26170394</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Seitz H, et al. Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-L2 vaccine. Cancer Prev Res. 2015;8(10):932&#8211;41.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-15-0164</pub-id><pub-id pub-id-type="pmid">26170394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pouyanfard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses</article-title><source>J Virol</source><year>2018</year><volume>92</volume><issue>4</issue><fpage>e01930</fpage><lpage>e2017</lpage><pub-id pub-id-type="doi">10.1128/JVI.01930-17</pub-id><pub-id pub-id-type="pmid">29212932</pub-id><pub-id pub-id-type="pmcid">PMC5790957</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Pouyanfard S, et al. Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses. J Virol. 2018;92(4):e01930-e2017.<pub-id pub-id-type="pmid">29212932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01930-17</pub-id><pub-id pub-id-type="pmcid">PMC5790957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spagnoli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-18177-1</pub-id><pub-id pub-id-type="pmid">29269879</pub-id><pub-id pub-id-type="pmcid">PMC5740060</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Spagnoli G, et al. Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles. Sci Rep. 2017;7(1):1&#8211;13.<pub-id pub-id-type="pmid">29269879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-18177-1</pub-id><pub-id pub-id-type="pmcid">PMC5740060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>3126</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.606569</pub-id><pub-id pub-id-type="pmcid">PMC7746619</pub-id><pub-id pub-id-type="pmid">33343580</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Yang F, et al. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles. Front Immunol. 2020;11:3126.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.606569</pub-id><pub-id pub-id-type="pmcid">PMC7746619</pub-id><pub-id pub-id-type="pmid">33343580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human Fc&#947;RI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>46</issue><fpage>5531</fpage><lpage>5539</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.10.009</pub-id><pub-id pub-id-type="pmid">27729176</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Zhang T, et al. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human Fc&#947;RI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types. Vaccine. 2016;34(46):5531&#8211;9.<pub-id pub-id-type="pmid">27729176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.10.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalnin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>37</issue><fpage>4942</fpage><lpage>4951</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.086</pub-id><pub-id pub-id-type="pmid">28778613</pub-id><pub-id pub-id-type="pmcid">PMC6454882</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Kalnin K, et al. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes. Vaccine. 2017;35(37):4942&#8211;51.<pub-id pub-id-type="pmid">28778613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.07.086</pub-id><pub-id pub-id-type="pmcid">PMC6454882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>30</issue><fpage>4022</fpage><lpage>4030</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.06.002</pub-id><pub-id pub-id-type="pmid">31213378</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Zhang T, et al. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types. Vaccine. 2019;37(30):4022&#8211;30.<pub-id pub-id-type="pmid">31213378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.06.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>11</issue><fpage>6127</fpage><lpage>6136</lpage><pub-id pub-id-type="doi">10.1128/JVI.03218-12</pub-id><pub-id pub-id-type="pmid">23536682</pub-id><pub-id pub-id-type="pmcid">PMC3648087</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Jagu S, et al. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol. 2013;87(11):6127&#8211;36.<pub-id pub-id-type="pmid">23536682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.03218-12</pub-id><pub-id pub-id-type="pmcid">PMC3648087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>S-W</given-names></name><etal/></person-group><article-title>Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>22</issue><fpage>3286</fpage><lpage>3294</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.009</pub-id><pub-id pub-id-type="pmid">22426329</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Yoon S-W, et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine. 2012;30(22):3286&#8211;94.<pub-id pub-id-type="pmid">22426329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.03.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namvar</surname><given-names>A</given-names></name><etal/></person-group><article-title>In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-51679-8</pub-id><pub-id pub-id-type="pmid">31645650</pub-id><pub-id pub-id-type="pmcid">PMC6811573</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Namvar A, et al. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Sci Rep. 2019;9(1):1&#8211;22.<pub-id pub-id-type="pmid">31645650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-51679-8</pub-id><pub-id pub-id-type="pmcid">PMC6811573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olczak</surname><given-names>P</given-names></name><etal/></person-group><article-title>RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer</article-title><source>J Virol</source><year>2022</year><volume>96</volume><issue>13</issue><fpage>e00566</fpage><lpage>e622</lpage><pub-id pub-id-type="doi">10.1128/jvi.00566-22</pub-id><pub-id pub-id-type="pmid">35703545</pub-id><pub-id pub-id-type="pmcid">PMC9278150</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Olczak P, et al. RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer. J Virol. 2022;96(13):e00566-e622.<pub-id pub-id-type="pmid">35703545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.00566-22</pub-id><pub-id pub-id-type="pmcid">PMC9278150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valencia</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><issue>8</issue><fpage>2748</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1875763</pub-id><pub-id pub-id-type="pmid">33573433</pub-id><pub-id pub-id-type="pmcid">PMC8475605</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Valencia SM, et al. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP. Hum Vaccin Immunother. 2021;17(8):2748&#8211;61.<pub-id pub-id-type="pmid">33573433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.1875763</pub-id><pub-id pub-id-type="pmcid">PMC8475605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Protein transduction domain can enhance the humoral immunity and cross-protection of HPV16L2 peptide vaccines</article-title><source>Biomed Rep</source><year>2016</year><volume>4</volume><issue>6</issue><fpage>746</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.3892/br.2016.647</pub-id><pub-id pub-id-type="pmid">27284417</pub-id><pub-id pub-id-type="pmcid">PMC4887978</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Li L, et al. Protein transduction domain can enhance the humoral immunity and cross-protection of HPV16L2 peptide vaccines. Biomed Rep. 2016;4(6):746&#8211;50.<pub-id pub-id-type="pmid">27284417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/br.2016.647</pub-id><pub-id pub-id-type="pmcid">PMC4887978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Harnessing self-assembled peptide nanoparticles in epitope vaccine design</article-title><source>Biotechnol Adv</source><year>2017</year><volume>35</volume><issue>5</issue><fpage>575</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2017.05.002</pub-id><pub-id pub-id-type="pmid">28522213</pub-id><pub-id pub-id-type="pmcid">PMC7127164</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Negahdaripour M, et al. Harnessing self-assembled peptide nanoparticles in epitope vaccine design. Biotechnol Adv. 2017;35(5):575&#8211;96.<pub-id pub-id-type="pmid">28522213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biotechadv.2017.05.002</pub-id><pub-id pub-id-type="pmcid">PMC7127164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>do Carmo Caldeira</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>27</issue><fpage>4384</fpage><lpage>4393</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.049</pub-id><pub-id pub-id-type="pmid">20434554</pub-id><pub-id pub-id-type="pmcid">PMC2881612</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">do Carmo Caldeira J, et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine. 2010;28(27):4384&#8211;93.<pub-id pub-id-type="pmid">20434554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.04.049</pub-id><pub-id pub-id-type="pmcid">PMC2881612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name><etal/></person-group><article-title>A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>8</issue><fpage>e23310</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0023310</pub-id><pub-id pub-id-type="pmid">21858066</pub-id><pub-id pub-id-type="pmcid">PMC3157372</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Tumban E, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE. 2011;6(8): e23310.<pub-id pub-id-type="pmid">21858066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0023310</pub-id><pub-id pub-id-type="pmcid">PMC3157372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17&#8211;36 epitopes</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>42</issue><fpage>5553</fpage><lpage>5563</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.005</pub-id><pub-id pub-id-type="pmid">26382603</pub-id><pub-id pub-id-type="pmcid">PMC4763949</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Jagu S, et al. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17&#8211;36 epitopes. Vaccine. 2015;33(42):5553&#8211;63.<pub-id pub-id-type="pmid">26382603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.09.005</pub-id><pub-id pub-id-type="pmcid">PMC4763949</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications</article-title><source>Virology</source><year>2006</year><volume>348</volume><issue>2</issue><fpage>475</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.12.039</pub-id><pub-id pub-id-type="pmid">16466765</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Smith ML, et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 2006;348(2):475&#8211;88.<pub-id pub-id-type="pmid">16466765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2005.12.039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>26</issue><fpage>5516</fpage><lpage>5525</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.058</pub-id><pub-id pub-id-type="pmid">16725236</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Palmer KE, et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine. 2006;24(26):5516&#8211;25.<pub-id pub-id-type="pmid">16725236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.04.058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#268;e&#345;ovsk&#225;</surname><given-names>N</given-names></name><etal/></person-group><article-title>Transient expression of HPV16 E7 peptide (aa 44&#8211;60) and HPV16 L2 peptide (aa 108&#8211;120) on chimeric potyvirus-like particles using Potato virus X-based vector</article-title><source>Protein Expr Purif</source><year>2008</year><volume>58</volume><issue>1</issue><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2007.09.006</pub-id><pub-id pub-id-type="pmid">17980618</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">&#268;e&#345;ovsk&#225; N, et al. Transient expression of HPV16 E7 peptide (aa 44&#8211;60) and HPV16 L2 peptide (aa 108&#8211;120) on chimeric potyvirus-like particles using Potato virus X-based vector. Protein Expr Purif. 2008;58(1):154&#8211;61.<pub-id pub-id-type="pmid">17980618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pep.2007.09.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Production and characterization of virus-like particles of grapevine fanleaf virus presenting L2 epitope of human papillomavirus minor capsid protein</article-title><source>BMC Biotechnol</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12896-019-0566-y</pub-id><pub-id pub-id-type="pmid">31752839</pub-id><pub-id pub-id-type="pmcid">PMC6868843</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Yazdani R, et al. Production and characterization of virus-like particles of grapevine fanleaf virus presenting L2 epitope of human papillomavirus minor capsid protein. BMC Biotechnol. 2019;19(1):1&#8211;12.<pub-id pub-id-type="pmid">31752839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12896-019-0566-y</pub-id><pub-id pub-id-type="pmcid">PMC6868843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawana</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><issue>27&#8211;30</issue><fpage>4256</fpage><lpage>4260</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00454-7</pub-id><pub-id pub-id-type="pmid">14505907</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Kawana K, et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine. 2003;21(27&#8211;30):4256&#8211;60.<pub-id pub-id-type="pmid">14505907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(03)00454-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio</surname><given-names>I</given-names></name><etal/></person-group><article-title>Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20&#8211;38) peptide displayed on bacterial thioredoxin</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>13</issue><fpage>1949</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.102</pub-id><pub-id pub-id-type="pmid">19368776</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Rubio I, et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20&#8211;38) peptide displayed on bacterial thioredoxin. Vaccine. 2009;27(13):1949&#8211;56.<pub-id pub-id-type="pmid">19368776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.01.102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariz</surname><given-names>FC</given-names></name><etal/></person-group><article-title>A broadly protective vaccine against cutaneous human papillomaviruses</article-title><source>npj Vaccines</source><year>2022</year><volume>7</volume><issue>1</issue><fpage>116</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00539-0</pub-id><pub-id pub-id-type="pmid">36216845</pub-id><pub-id pub-id-type="pmcid">PMC9550855</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Mariz FC, et al. A broadly protective vaccine against cutaneous human papillomaviruses. npj Vaccines. 2022;7(1):116.<pub-id pub-id-type="pmid">36216845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-022-00539-0</pub-id><pub-id pub-id-type="pmcid">PMC9550855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alphs</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2</article-title><source>Proc Natl Acad Sci</source><year>2008</year><volume>105</volume><issue>15</issue><fpage>5850</fpage><lpage>5855</lpage><pub-id pub-id-type="doi">10.1073/pnas.0800868105</pub-id><pub-id pub-id-type="pmid">18413606</pub-id><pub-id pub-id-type="pmcid">PMC2299222</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Alphs HH, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci. 2008;105(15):5850&#8211;5.<pub-id pub-id-type="pmid">18413606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0800868105</pub-id><pub-id pub-id-type="pmcid">PMC2299222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalnin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>28</issue><fpage>3540</fpage><lpage>3547</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.032</pub-id><pub-id pub-id-type="pmid">24780250</pub-id><pub-id pub-id-type="pmcid">PMC4332780</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Kalnin K, et al. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine. 2014;32(28):3540&#8211;7.<pub-id pub-id-type="pmid">24780250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.04.032</pub-id><pub-id pub-id-type="pmcid">PMC4332780</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Production and preliminary in vivo evaluations of a novel in silico-designed L2-based potential HPV vaccine</article-title><source>Curr Pharm Biotechnol</source><year>2020</year><volume>21</volume><issue>4</issue><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.2174/1389201020666191114104850</pub-id><pub-id pub-id-type="pmid">31729940</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Negahdaripour M, et al. Production and preliminary in vivo evaluations of a novel in silico-designed L2-based potential HPV vaccine. Curr Pharm Biotechnol. 2020;21(4):316&#8211;24.<pub-id pub-id-type="pmid">31729940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389201020666191114104850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A Tat-conjugated peptide nucleic acid Tat-PNA-DR inhibits hepatitis B virus replication in vitro and in vivo by targeting LTR direct repeats of HBV RNA</article-title><source>Mol Therapy-Nucleic Acids</source><year>2016</year><volume>5</volume><fpage>e295</fpage><pub-id pub-id-type="doi">10.1038/mtna.2016.11</pub-id><pub-id pub-id-type="pmcid">PMC5014453</pub-id><pub-id pub-id-type="pmid">26978579</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Zeng Z, et al. A Tat-conjugated peptide nucleic acid Tat-PNA-DR inhibits hepatitis B virus replication in vitro and in vivo by targeting LTR direct repeats of HBV RNA. Mol Therapy-Nucleic Acids. 2016;5:e295.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtna.2016.11</pub-id><pub-id pub-id-type="pmcid">PMC5014453</pub-id><pub-id pub-id-type="pmid">26978579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghian</surname><given-names>I</given-names></name><etal/></person-group><article-title>Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines</article-title><source>Eur J Pharm Sci</source><year>2022</year><volume>169</volume><fpage>106094</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2021.106094</pub-id><pub-id pub-id-type="pmid">34896590</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Sadeghian I, et al. Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. Eur J Pharm Sci. 2022;169: 106094.<pub-id pub-id-type="pmid">34896590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2021.106094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Small extracellular vesicles (sEVs): Discovery, functions, applications, detection methods and various engineered forms</article-title><source>Expert Opin Biol Ther</source><year>2021</year><volume>21</volume><issue>3</issue><fpage>371</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1080/14712598.2021.1825677</pub-id><pub-id pub-id-type="pmid">32945228</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Negahdaripour M, et al. Small extracellular vesicles (sEVs): Discovery, functions, applications, detection methods and various engineered forms. Expert Opin Biol Ther. 2021;21(3):371&#8211;94.<pub-id pub-id-type="pmid">32945228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14712598.2021.1825677</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Bonito</surname><given-names>P</given-names></name><etal/></person-group><article-title>Anti-cancer vaccine for HPV-associated neoplasms: focus on a therapeutic HPV vaccine based on a novel tumor antigen delivery method using endogenously engineered exosomes</article-title><source>Cancers</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>138</fpage><pub-id pub-id-type="doi">10.3390/cancers11020138</pub-id><pub-id pub-id-type="pmid">30682811</pub-id><pub-id pub-id-type="pmcid">PMC6406600</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Di Bonito P, et al. Anti-cancer vaccine for HPV-associated neoplasms: focus on a therapeutic HPV vaccine based on a novel tumor antigen delivery method using endogenously engineered exosomes. Cancers. 2019;11(2):138.<pub-id pub-id-type="pmid">30682811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11020138</pub-id><pub-id pub-id-type="pmcid">PMC6406600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines</article-title><source>JNCI J Nat Cancer Inst</source><year>2009</year><volume>101</volume><issue>11</issue><fpage>782</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp106</pub-id><pub-id pub-id-type="pmid">19470949</pub-id><pub-id pub-id-type="pmcid">PMC2689872</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Jagu S, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. JNCI J Nat Cancer Inst. 2009;101(11):782&#8211;92.<pub-id pub-id-type="pmid">19470949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djp106</pub-id><pub-id pub-id-type="pmcid">PMC2689872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>28</issue><fpage>4478</fpage><lpage>4486</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.039</pub-id><pub-id pub-id-type="pmid">20434552</pub-id><pub-id pub-id-type="pmcid">PMC2918737</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Jagu S, et al. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine. 2010;28(28):4478&#8211;86.<pub-id pub-id-type="pmid">20434552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.04.039</pub-id><pub-id pub-id-type="pmcid">PMC2918737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Optimization of multimeric human papillomavirus L2 vaccines</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>e55538</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055538</pub-id><pub-id pub-id-type="pmid">23383218</pub-id><pub-id pub-id-type="pmcid">PMC3561222</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Jagu S, et al. Optimization of multimeric human papillomavirus L2 vaccines. PLoS ONE. 2013;8(1): e55538.<pub-id pub-id-type="pmid">23383218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0055538</pub-id><pub-id pub-id-type="pmcid">PMC3561222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hitzeroth</surname><given-names>II</given-names></name><etal/></person-group><article-title>Immunogenicity of an HPV-16 L2 DNA vaccine</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>46</issue><fpage>6432</fpage><lpage>6434</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.015</pub-id><pub-id pub-id-type="pmid">19559114</pub-id><pub-id pub-id-type="pmcid">PMC2767434</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Hitzeroth II, et al. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine. 2009;27(46):6432&#8211;4.<pub-id pub-id-type="pmid">19559114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.06.015</pub-id><pub-id pub-id-type="pmcid">PMC2767434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namvar</surname><given-names>A</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>M</given-names></name></person-group><article-title>HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer</article-title><source>Bratisl Lek Listy</source><year>2016</year><volume>117</volume><issue>3</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">26925750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4149/bll_2016_034</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Namvar A, Bolhassani A, Hashemi M. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer. Bratisl Lek Listy. 2016;117(3):179&#8211;84.<pub-id pub-id-type="pmid">26925750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4149/bll_2016_034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2020</year><volume>107</volume><issue>3</issue><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2020.02.031</pub-id><pub-id pub-id-type="pmid">32151670</pub-id><pub-id pub-id-type="pmcid">PMC7705948</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Hasan Y, et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2020;107(3):487&#8211;98.<pub-id pub-id-type="pmid">32151670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2020.02.031</pub-id><pub-id pub-id-type="pmcid">PMC7705948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vo</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Enhanced immunogenicity of adjuvanted microparticulate HPV16 vaccines administered via the transdermal route</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><issue>9</issue><fpage>1128</fpage><pub-id pub-id-type="doi">10.3390/ph15091128</pub-id><pub-id pub-id-type="pmid">36145349</pub-id><pub-id pub-id-type="pmcid">PMC9503878</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Vo TP, et al. Enhanced immunogenicity of adjuvanted microparticulate HPV16 vaccines administered via the transdermal route. Pharmaceuticals. 2022;15(9):1128.<pub-id pub-id-type="pmid">36145349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph15091128</pub-id><pub-id pub-id-type="pmcid">PMC9503878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>MN</given-names></name><name name-style="western"><surname>Kouzi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>MD</given-names></name></person-group><article-title>Strategies for developing oral vaccines for human papillomavirus (HPV) induced cancer using nanoparticle mediated delivery system</article-title><source>J Pharm Pharm Sci</source><year>2015</year><volume>18</volume><issue>2</issue><fpage>220</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.18433/J3RS3V</pub-id><pub-id pub-id-type="pmid">26158287</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Uddin MN, Kouzi SA, Hussain MD. Strategies for developing oral vaccines for human papillomavirus (HPV) induced cancer using nanoparticle mediated delivery system. J Pharm Pharm Sci. 2015;18(2):220&#8211;34.<pub-id pub-id-type="pmid">26158287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18433/j3rs3v</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sloat</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles</article-title><source>J Control Release</source><year>2010</year><volume>141</volume><issue>1</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2009.08.023</pub-id><pub-id pub-id-type="pmid">19729045</pub-id><pub-id pub-id-type="pmcid">PMC2789915</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Sloat BR, et al. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release. 2010;141(1):93&#8211;100.<pub-id pub-id-type="pmid">19729045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2009.08.023</pub-id><pub-id pub-id-type="pmcid">PMC2789915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraillery</surname><given-names>D</given-names></name><etal/></person-group><article-title>Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever</article-title><source>Clin Vaccine Immunol</source><year>2007</year><volume>14</volume><issue>10</issue><fpage>1285</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1128/CVI.00164-07</pub-id><pub-id pub-id-type="pmid">17687110</pub-id><pub-id pub-id-type="pmcid">PMC2168124</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Fraillery D, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14(10):1285&#8211;95.<pub-id pub-id-type="pmid">17687110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00164-07</pub-id><pub-id pub-id-type="pmcid">PMC2168124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuck</surname><given-names>D</given-names></name><etal/></person-group><article-title>Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1</article-title><source>J Virol</source><year>2006</year><volume>80</volume><issue>6</issue><fpage>2621</fpage><lpage>2630</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.6.2621-2630.2006</pub-id><pub-id pub-id-type="pmid">16501072</pub-id><pub-id pub-id-type="pmcid">PMC1395428</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Kuck D, et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol. 2006;80(6):2621&#8211;30.<pub-id pub-id-type="pmid">16501072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.80.6.2621-2630.2006</pub-id><pub-id pub-id-type="pmcid">PMC1395428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques</article-title><source>Hum Gene Ther</source><year>2012</year><volume>23</volume><issue>7</issue><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1089/hum.2011.202</pub-id><pub-id pub-id-type="pmid">22401308</pub-id><pub-id pub-id-type="pmcid">PMC3404423</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Nieto K, et al. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther. 2012;23(7):733&#8211;41.<pub-id pub-id-type="pmid">22401308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2011.202</pub-id><pub-id pub-id-type="pmcid">PMC3404423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors</article-title><source>Antivir Ther</source><year>2009</year><volume>14</volume><issue>8</issue><fpage>1125</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.3851/IMP1469</pub-id><pub-id pub-id-type="pmid">20032542</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Nieto K, et al. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir Ther. 2009;14(8):1125&#8211;37.<pub-id pub-id-type="pmid">20032542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3851/IMP1469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The COVID-19 vaccine race: challenges and opportunities in vaccine formulation</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id><pub-id pub-id-type="pmid">32761294</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Wang J, et al. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020;21:1&#8211;12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id><pub-id pub-id-type="pmid">32761294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illah</surname><given-names>O</given-names></name><name name-style="western"><surname>Olaitan</surname><given-names>A</given-names></name></person-group><article-title>Updates on HPV vaccination</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><issue>2</issue><fpage>243</fpage><pub-id pub-id-type="doi">10.3390/diagnostics13020243</pub-id><pub-id pub-id-type="pmid">36673053</pub-id><pub-id pub-id-type="pmcid">PMC9857409</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Illah O, Olaitan A. Updates on HPV vaccination. Diagnostics. 2023;13(2):243.<pub-id pub-id-type="pmid">36673053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13020243</pub-id><pub-id pub-id-type="pmcid">PMC9857409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>A-L</given-names></name></person-group><article-title>Recent developments in human papillomavirus (HPV) vaccinology</article-title><source>Viruses</source><year>2023</year><volume>15</volume><issue>7</issue><fpage>1440</fpage><pub-id pub-id-type="doi">10.3390/v15071440</pub-id><pub-id pub-id-type="pmid">37515128</pub-id><pub-id pub-id-type="pmcid">PMC10384715</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Williamson A-L. Recent developments in human papillomavirus (HPV) vaccinology. Viruses. 2023;15(7):1440.<pub-id pub-id-type="pmid">37515128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v15071440</pub-id><pub-id pub-id-type="pmcid">PMC10384715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA a Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer J Clin. 2021;71(3):209&#8211;49.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>